[P02BB01, trichlorfon, The therapeutic efficacy of Metrifonate can be decreased when used in combination with Difluocortolone.]
[S02DA03, antipyrine, The risk or severity of gastrointestinal irritation can be increased when Difluocortolone is combined with Antipyrine.]
[A14AA02, stanozolol, The risk or severity of fluid retention can be increased when Difluocortolone is combined with Stanozolol.]
[G03XB02, ulipristal, The serum concentration of Difluocortolone can be increased when it is combined with Ulipristal.]
[J01GA01, streptomycin, Difluocortolone may decrease the excretion rate of Streptomycin which could result in a higher serum level.]
[L04AA04, rabbit anti-human T-lymphocyte globulin, The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Difluocortolone.]
[L01AD04, streptozocin, The risk or severity of adverse effects can be increased when Streptozocin is combined with Difluocortolone.]
[L04AA27, fingolimod, Difluocortolone may increase the immunosuppressive activities of Fingolimod.]
[M03AB01, succinylcholine, The risk or severity of myopathy and weakness can be increased when Succinylcholine is combined with Difluocortolone.]
[A02BX02, sucralfate, Sucralfate may decrease the excretion rate of Difluocortolone which could result in a higher serum level.]
[J01CG01, sulbactam, Difluocortolone may decrease the excretion rate of Sulbactam which could result in a higher serum level.]
[J01EC02, sulfadiazine, The risk or severity of hyperglycemia can be increased when Difluocortolone is combined with Sulfadiazine.]
[J01EC01, sulfamethoxazole, The risk or severity of myelosuppression can be increased when Sulfamethoxazole is combined with Difluocortolone.]
[S01AB02, sulfisoxazole, The risk or severity of hyperglycemia can be increased when Difluocortolone is combined with Sulfisoxazole.]
[M01AB02, sulindac, The risk or severity of gastrointestinal irritation can be increased when Difluocortolone is combined with Sulindac.]
[N05AL01, sulpiride, The therapeutic efficacy of Sulpiride can be decreased when used in combination with Difluocortolone.]
[A10BB04, glibornuride, The risk or severity of hyperglycemia can be increased when Difluocortolone is combined with Glibornuride.]
[A10BC01, glymidine, The risk or severity of hyperglycemia can be increased when Difluocortolone is combined with Glymidine.]
[M01AX04, apazone, The risk or severity of gastrointestinal irritation can be increased when Difluocortolone is combined with Azapropazone.]
[L01BB02, mercaptopurine, The risk or severity of adverse effects can be increased when Mercaptopurine is combined with Difluocortolone.]
[N06DA01, tacrine, The therapeutic efficacy of Tacrine can be decreased when used in combination with Difluocortolone.]
[L02BA01, tamoxifen, The metabolism of Tamoxifen can be increased when combined with Difluocortolone.]
[N05CD07, temazepam, Temazepam may decrease the excretion rate of Difluocortolone which could result in a higher serum level.]
[L01CB02, teniposide, The metabolism of Teniposide can be increased when combined with Difluocortolone.]
[R03CC03, terbutaline, The therapeutic efficacy of Terbutaline can be decreased when used in combination with Difluocortolone.]
[B01AE07, dabigatran etexilate, Dabigatran etexilate may decrease the excretion rate of Difluocortolone which could result in a higher serum level.]
[G03BA03, testosterone, The risk or severity of edema formation can be increased when Testosterone is combined with Difluocortolone.]
[S03AA02, tetracycline, Tetracycline may decrease the excretion rate of Difluocortolone which could result in a higher serum level.]
[J01DI02, ceftaroline fosamil, Ceftaroline fosamil may decrease the excretion rate of Difluocortolone which could result in a higher serum level.]
[N04BC07, apomorphine, The metabolism of Apomorphine can be increased when combined with Difluocortolone.]
[L04AX02, thalidomide, The risk or severity of adverse effects can be increased when Thalidomide is combined with Difluocortolone.]
[R03DA07, theobromine, Theobromine may increase the excretion rate of Difluocortolone which could result in a lower serum level and potentially a reduction in efficacy.]
[R03DA04, theophylline, The metabolism of Theophylline can be increased when combined with Difluocortolone.]
[P02CA02, thiabendazole, Thiabendazole may decrease the excretion rate of Difluocortolone which could result in a higher serum level.]
[L01XX41, eribulin, The risk or severity of adverse effects can be increased when Eribulin is combined with Difluocortolone.]
[R06AD03, thiethylperazine, Thiethylperazine may decrease the excretion rate of Difluocortolone which could result in a higher serum level.]
[L01AC01, thiotepa, The therapeutic efficacy of Thiotepa can be decreased when used in combination with Difluocortolone.]
[L01BB03, thioguanine, The risk or severity of adverse effects can be increased when Tioguanine is combined with Difluocortolone.]
[B02AB01, aprotinin, The therapeutic efficacy of Aprotinin can be decreased when used in combination with Difluocortolone.]
[G04BE06, moxisylyte, Difluocortolone may decrease the excretion rate of Moxisylyte which could result in a higher serum level.]
[N05AL03, tiapride, Difluocortolone may decrease the excretion rate of Tiapride which could result in a higher serum level.]
[B01AC05, ticlopidine, Ticlopidine may decrease the excretion rate of Difluocortolone which could result in a higher serum level.]
[S01ED01, timolol, Timolol may decrease the excretion rate of Difluocortolone which could result in a higher serum level.]
[P01AB02, tinidazole, Tinidazole may decrease the excretion rate of Difluocortolone which could result in a higher serum level.]
[S01AA12, tobramycin, Difluocortolone may decrease the excretion rate of Tobramycin which could result in a higher serum level.]
[A10BB05, tolazamide, The risk or severity of hyperglycemia can be increased when Difluocortolone is combined with Tolazamide.]
[V04CA01, tolbutamide, The risk or severity of hyperglycemia can be increased when Difluocortolone is combined with Tolbutamide.]
[M02AA21, tolmetin, The risk or severity of gastrointestinal irritation can be increased when Difluocortolone is combined with Tolmetin.]
[N02AX02, tramadol, Tramadol may decrease the excretion rate of Difluocortolone which could result in a higher serum level.]
[N06AX05, trazodone, The metabolism of Trazodone can be increased when combined with Difluocortolone.]
[L01XF01, tretinoin, The risk or severity of adverse effects can be increased when Tretinoin is combined with Difluocortolone.]
[S01BA05, triamcinolone, The risk or severity of adverse effects can be increased when Triamcinolone is combined with Difluocortolone.]
[C03DB02, triamterene, Triamterene may increase the excretion rate of Difluocortolone which could result in a lower serum level and potentially a reduction in efficacy.]
[N05CD05, triazolam, The metabolism of Triazolam can be increased when combined with Difluocortolone.]
[C03AA06, trichlormethiazide, The risk or severity of electrolyte imbalance can be increased when Difluocortolone is combined with Trichlormethiazide.]
[S01EB04, demecarium, The therapeutic efficacy of Demecarium can be decreased when used in combination with Difluocortolone.]
[A16AX12, trientine, Triethylenetetramine may decrease the excretion rate of Difluocortolone which could result in a higher serum level.]
[S01AD02, trifluridine, The risk or severity of adverse effects can be increased when Trifluridine is combined with Difluocortolone.]
[N05AA05, triflupromazine, The therapeutic efficacy of Triflupromazine can be decreased when used in combination with Difluocortolone.]
[D07AC02, fluclorolone, The risk or severity of adverse effects can be increased when Difluocortolone is combined with Fluclorolone.]
[R03BA07, mometasone, The risk or severity of adverse effects can be increased when Mometasone is combined with Difluocortolone.]
[A03AA05, trimebutine, Trimebutine may decrease the excretion rate of Difluocortolone which could result in a higher serum level.]
[J01EA01, trimethoprim, Trimethoprim may decrease the excretion rate of Difluocortolone which could result in a higher serum level.]
[J01FA08, troleandomycin, The metabolism of Difluocortolone can be decreased when combined with Troleandomycin.]
[M03AA02, tubocurarine, The therapeutic efficacy of Tubocurarine can be decreased when used in combination with Difluocortolone.]
[R03DX07, roflumilast, Roflumilast may increase the immunosuppressive activities of Difluocortolone.]
[L04AA26, belimumab, The risk or severity of adverse effects can be increased when Belimumab is combined with Difluocortolone.]
[L01FX04, ipilimumab, Ipilimumab may decrease the excretion rate of Difluocortolone which could result in a higher serum level.]
[S01AA05, tyrothricin, The therapeutic efficacy of Tyrothricin can be decreased when used in combination with Difluocortolone.]
[L01EX04, vandetanib, The metabolism of Vandetanib can be increased when combined with Difluocortolone.]
[R02AA14, oxyquinoline, Difluocortolone may decrease the excretion rate of Oxyquinoline which could result in a higher serum level.]
[A10BH05, linagliptin, The risk or severity of hyperglycemia can be increased when Difluocortolone is combined with Linagliptin.]
[J05AP03, boceprevir, The metabolism of Difluocortolone can be decreased when combined with Boceprevir.]
[J05AP02, telaprevir, The metabolism of Difluocortolone can be decreased when combined with Telaprevir.]
[J05AG05, rilpivirine, The serum concentration of Rilpivirine can be decreased when it is combined with Difluocortolone.]
[S01AA28, vancomycin, Difluocortolone may decrease the excretion rate of Vancomycin which could result in a higher serum level.]
[L04AA28, belatacept, The risk or severity of adverse effects can be increased when Belatacept is combined with Difluocortolone.]
[N03AX21, ezogabine, Ezogabine may decrease the excretion rate of Difluocortolone which could result in a higher serum level.]
[B01AF01, rivaroxaban, The metabolism of Rivaroxaban can be increased when combined with Difluocortolone.]
[R03AC18, indacaterol, The risk or severity of hypokalemia can be increased when Difluocortolone is combined with Indacaterol.]
[B01AC24, ticagrelor, The metabolism of Ticagrelor can be increased when combined with Difluocortolone.]
[C08DA01, verapamil, The metabolism of Difluocortolone can be decreased when combined with Verapamil.]
[N06AX09, viloxazine, The metabolism of Difluocortolone can be decreased when combined with Viloxazine.]
[L01CA01, vinblastine, The metabolism of Vinblastine can be increased when combined with Difluocortolone.]
[L01CA02, vincristine, The metabolism of Vincristine can be increased when combined with Difluocortolone.]
[L01CA03, vindesine, The metabolism of Vindesine can be increased when combined with Difluocortolone.]
[B03BA01, vitamin B12, Cyanocobalamin may decrease the excretion rate of Difluocortolone which could result in a higher serum level.]
[B01AA03, warfarin, Difluocortolone may increase the anticoagulant activities of Warfarin.]
[C03BA10, xipamide, Xipamide may increase the excretion rate of Difluocortolone which could result in a lower serum level and potentially a reduction in efficacy.]
[J05AF01, zidovudine, The risk or severity of adverse effects can be increased when Zidovudine is combined with Difluocortolone.]
[N05AF05, zuclopenthixol, The metabolism of Zuclopenthixol can be increased when combined with Difluocortolone.]
[J05AE02, indinavir, The metabolism of Difluocortolone can be decreased when combined with Indinavir.]
[L01EC01, vemurafenib, The metabolism of Vemurafenib can be increased when combined with Difluocortolone.]
[M05BA03, pamidronic acid, Pamidronic acid may decrease the excretion rate of Difluocortolone which could result in a higher serum level.]
[L01FX05, brentuximab vedotin, The metabolism of Brentuximab vedotin can be increased when combined with Difluocortolone.]
[M05BA05, tiludronic acid, Tiludronic acid may decrease the excretion rate of Difluocortolone which could result in a higher serum level.]
[B06AC02, icatibant, Icatibant may decrease the excretion rate of Difluocortolone which could result in a higher serum level.]
[L01ED01, crizotinib, The metabolism of Crizotinib can be increased when combined with Difluocortolone.]
[A02BC04, rabeprazole, Rabeprazole may decrease the excretion rate of Difluocortolone which could result in a higher serum level.]
[H05BX03, doxercalciferol, The therapeutic efficacy of Doxercalciferol can be decreased when used in combination with Difluocortolone.]
[J01MA13, trovafloxacin, The risk or severity of tendinopathy can be increased when Difluocortolone is combined with Trovafloxacin.]
[N05AE04, ziprasidone, The metabolism of Difluocortolone can be decreased when combined with Ziprasidone.]
[G03AC10, drospirenone, The serum concentration of Difluocortolone can be increased when it is combined with Drospirenone.]
[V03AC02, deferiprone, Deferiprone may decrease the excretion rate of Difluocortolone which could result in a higher serum level.]
[L04AA34, alemtuzumab, The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Difluocortolone.]
[N02BA01, aspirin, The risk or severity of adverse effects can be increased when Difluocortolone is combined with Acetylsalicylic acid.]
[L01EJ01, ruxolitinib, The metabolism of Ruxolitinib can be increased when combined with Difluocortolone.]
[G04BD07, tolterodine, Tolterodine may decrease the excretion rate of Difluocortolone which could result in a higher serum level.]
[J01DH04, doripenem, Doripenem may decrease the excretion rate of Difluocortolone which could result in a higher serum level.]
[L03AB11, peginterferon alfa-2a, The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Difluocortolone.]
[A11CC03, alfacalcidol, The therapeutic efficacy of Alfacalcidol can be decreased when used in combination with Difluocortolone.]
[L01FA01, rituximab, The risk or severity of adverse effects can be increased when Rituximab is combined with Difluocortolone.]
[J02AC03, voriconazole, The serum concentration of Difluocortolone can be increased when it is combined with Voriconazole.]
[M03AC04, atracurium, The risk or severity of myopathy and weakness can be increased when Atracurium is combined with Difluocortolone.]
[M01CB03, auranofin, Auranofin may decrease the excretion rate of Difluocortolone which could result in a higher serum level.]
[L01EK01, axitinib, The metabolism of Axitinib can be increased when combined with Difluocortolone.]
[R07AX02, ivacaftor, The metabolism of Ivacaftor can be increased when combined with Difluocortolone.]
[H02AB11, prednylidene, The risk or severity of adverse effects can be increased when Difluocortolone is combined with Prednylidene.]
[B03XA04, peginesatide, Peginesatide may decrease the excretion rate of Difluocortolone which could result in a higher serum level.]
[L01BC07, azacitidine, The risk or severity of adverse effects can be increased when Azacitidine is combined with Difluocortolone.]
[L04AX01, azathioprine, The risk or severity of adverse effects can be increased when Azathioprine is combined with Difluocortolone.]
[L01BC05, gemcitabine, The risk or severity of adverse effects can be increased when Gemcitabine is combined with Difluocortolone.]
[J01DF01, aztreonam, Aztreonam may decrease the excretion rate of Difluocortolone which could result in a higher serum level.]
[R02AB04, bacitracin, Bacitracin may decrease the excretion rate of Difluocortolone which could result in a higher serum level.]
[G04BE10, avanafil, The serum concentration of Avanafil can be increased when it is combined with Difluocortolone.]
[M03BX01, baclofen, Baclofen may decrease the excretion rate of Difluocortolone which could result in a higher serum level.]
[J07BK01, varicella-zoster virus vaccine live (Oka-Merck) strain, The risk or severity of infection can be increased when Varicella zoster vaccine (live/attenuated) is combined with Difluocortolone.]
[L01FX02, gemtuzumab ozogamicin, The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Difluocortolone.]
[A08AA11, lorcaserin, Lorcaserin may decrease the excretion rate of Difluocortolone which could result in a higher serum level.]
[G04BD12, mirabegron, Mirabegron may decrease the excretion rate of Difluocortolone which could result in a higher serum level.]
[L01XG02, carfilzomib, The risk or severity of adverse effects can be increased when Carfilzomib is combined with Difluocortolone.]
[V03AX03, cobicistat, The metabolism of Difluocortolone can be decreased when combined with Cobicistat.]
[J05AJ02, elvitegravir, The metabolism of Difluocortolone can be decreased when combined with Elvitegravir.]
[L02BB04, enzalutamide, The serum concentration of Difluocortolone can be decreased when it is combined with Enzalutamide.]
[L01EA04, bosutinib, The metabolism of Bosutinib can be increased when combined with Difluocortolone.]
[L04AA31, teriflunomide, The risk or severity of adverse effects can be increased when Teriflunomide is combined with Difluocortolone.]
[A02AA05, magnesium silicate, The bioavailability of Difluocortolone can be decreased when combined with Magnesium silicate.]
[A02AC02, calcium silicate, The bioavailability of Difluocortolone can be decreased when combined with Calcium silicate.]
[L04AA22, abetimus, The risk or severity of adverse effects can be increased when Abetimus is combined with Difluocortolone.]
[H02AA01, aldosterone, The risk or severity of adverse effects can be increased when Aldosterone is combined with Difluocortolone.]
[L01EX05, regorafenib, The metabolism of Regorafenib can be increased when combined with Difluocortolone.]
[C01AA01, acetyldigitoxin, The risk or severity of adverse effects can be increased when Difluocortolone is combined with Acetyldigitoxin.]
[D02BA02, octinoxate, Difluocortolone may decrease the excretion rate of Octinoxate which could result in a higher serum level.]
[J05AE04, nelfinavir, The metabolism of Difluocortolone can be decreased when combined with Nelfinavir.]
[L01AA09, bendamustine, The risk or severity of adverse effects can be increased when Bendamustine is combined with Difluocortolone.]
[N04BD02, rasagiline, Rasagiline may decrease the excretion rate of Difluocortolone which could result in a higher serum level.]
[C08CA13, lercanidipine, The metabolism of Lercanidipine can be increased when combined with Difluocortolone.]
[N06DA02, donepezil, The therapeutic efficacy of Donepezil can be decreased when used in combination with Difluocortolone.]
[N03AX22, perampanel, The metabolism of Perampanel can be increased when combined with Difluocortolone.]
[L04AA29, tofacitinib, Difluocortolone may increase the immunosuppressive activities of Tofacitinib.]
[V09IX04, fluorodeoxyglucose F18, Difluocortolone may decrease the excretion rate of Fludeoxyglucose (18F) which could result in a higher serum level.]
[G04BE03, sildenafil, The metabolism of Sildenafil can be increased when combined with Difluocortolone.]
[V08CA11, gadofosveset, Gadofosveset trisodium may decrease the excretion rate of Difluocortolone which could result in a higher serum level.]
[L01EA05, ponatinib, The metabolism of Ponatinib can be increased when combined with Difluocortolone.]
[B01AF02, apixaban, The metabolism of Apixaban can be increased when combined with Difluocortolone.]
[A16AX08, teduglutide, Teduglutide may decrease the excretion rate of Difluocortolone which could result in a higher serum level.]
[C10AX12, lomitapide, The metabolism of Lomitapide can be increased when combined with Difluocortolone.]
[A10BH04, alogliptin, The risk or severity of hyperglycemia can be increased when Difluocortolone is combined with Alogliptin.]
[A16AX09, glycerol phenylbutyrate, The therapeutic efficacy of Glycerol phenylbutyrate can be decreased when used in combination with Difluocortolone.]
[C03AA01, bendroflumethiazide, The risk or severity of electrolyte imbalance can be increased when Difluocortolone is combined with Bendroflumethiazide.]
[L04AX06, pomalidomide, The metabolism of Pomalidomide can be increased when combined with Difluocortolone.]
[N02BA10, benorilate, The risk or severity of gastrointestinal irritation can be increased when Difluocortolone is combined with Benorilate.]
[A10BK02, canagliflozin, The risk or severity of hyperglycemia can be increased when Difluocortolone is combined with Canagliflozin.]
[L04AX07, dimethyl fumarate, The risk or severity of adverse effects can be increased when Dimethyl fumarate is combined with Difluocortolone.]
[J01MA15, gemifloxacin, The risk or severity of tendinopathy can be increased when Difluocortolone is combined with Gemifloxacin.]
[S01AE07, moxifloxacin, The risk or severity of tendinopathy can be increased when Difluocortolone is combined with Moxifloxacin.]
[H03AA04, tiratricol, The therapeutic efficacy of Tiratricol can be decreased when used in combination with Difluocortolone.]
[A10AE05, insulin detemir, The risk or severity of hyperglycemia can be increased when Difluocortolone is combined with Insulin detemir.]
[A10BX05, pramlintide, The risk or severity of hyperglycemia can be increased when Difluocortolone is combined with Pramlintide.]
[L03AA12, ancestim, Difluocortolone may decrease the excretion rate of Ancestim which could result in a higher serum level.]
[M01AH01, celecoxib, The risk or severity of gastrointestinal irritation can be increased when Difluocortolone is combined with Celecoxib.]
[L04AA18, everolimus, The metabolism of Everolimus can be increased when combined with Difluocortolone.]
[N04AC01, benztropine, Benzatropine may decrease the excretion rate of Difluocortolone which could result in a higher serum level.]
[L01EC02, dabrafenib, The serum concentration of Difluocortolone can be decreased when it is combined with Dabrafenib.]
[R02AX03, benzydamine, The risk or severity of gastrointestinal irritation can be increased when Difluocortolone is combined with Benzydamine.]
[L01EE01, trametinib, Trametinib may decrease the excretion rate of Difluocortolone which could result in a higher serum level.]
[V09AX05, florbetapir F-18, Difluocortolone may decrease the excretion rate of Florbetapir (18F) which could result in a higher serum level.]
[N06AX28, levomilnacipran, Levomilnacipran may decrease the excretion rate of Difluocortolone which could result in a higher serum level.]
[A10BJ03, lixisenatide, The risk or severity of hyperglycemia can be increased when Difluocortolone is combined with Lixisenatide.]
[C02KX04, macitentan, Macitentan may decrease the excretion rate of Difluocortolone which could result in a higher serum level.]
[L01EL01, ibrutinib, The risk or severity of adverse effects can be increased when Ibrutinib is combined with Difluocortolone.]
[N06AX26, vortioxetine, The metabolism of Vortioxetine can be increased when combined with Difluocortolone.]
[G03AC08, etonogestrel, The serum concentration of Difluocortolone can be increased when it is combined with Etonogestrel.]
[J05AP05, simeprevir, The metabolism of Difluocortolone can be decreased when combined with Simeprevir.]
[J05AP08, sofosbuvir, Sofosbuvir may decrease the excretion rate of Difluocortolone which could result in a higher serum level.]
[A10BK01, dapagliflozin, The risk or severity of hyperglycemia can be increased when Difluocortolone is combined with Dapagliflozin.]
[C01CA27, droxidopa, The risk or severity of hypokalemia can be increased when Difluocortolone is combined with Droxidopa.]
[N05CH03, tasimelteon, The metabolism of Tasimelteon can be increased when combined with Difluocortolone.]
[A16AA07, metreleptin, The metabolism of Difluocortolone can be increased when combined with Metreleptin.]
[L04AA32, apremilast, The risk or severity of adverse effects can be increased when Apremilast is combined with Difluocortolone.]
[L02BG02, formestane, The risk or severity of edema formation can be increased when Formestane is combined with Difluocortolone.]
[A16AA06, betaine, The therapeutic efficacy of Betaine can be decreased when used in combination with Difluocortolone.]
[S03BA03, betamethasone, The risk or severity of adverse effects can be increased when Betamethasone is combined with Difluocortolone.]
[V03AB34, fomepizole, Fomepizole may decrease the excretion rate of Difluocortolone which could result in a higher serum level.]
[A10BJ04, albiglutide, The risk or severity of hyperglycemia can be increased when Difluocortolone is combined with Albiglutide.]
[L04AC11, siltuximab, The risk or severity of adverse effects can be increased when Siltuximab is combined with Difluocortolone.]
[L01ED02, ceritinib, The risk or severity of hyperglycemia can be increased when Difluocortolone is combined with Ceritinib.]
[B01AC26, vorapaxar, The metabolism of Vorapaxar can be increased when combined with Difluocortolone.]
[L04AA33, vedolizumab, The risk or severity of adverse effects can be increased when Vedolizumab is combined with Difluocortolone.]
[B01AA07, acenocoumarol, Difluocortolone may increase the anticoagulant activities of Acenocoumarol.]
[L01XH04, belinostat, The risk or severity of adverse effects can be increased when Belinostat is combined with Difluocortolone.]
[L01EM01, idelalisib, The metabolism of Idelalisib can be increased when combined with Difluocortolone.]
[A10BK03, empagliflozin, The risk or severity of hyperglycemia can be increased when Difluocortolone is combined with Empagliflozin.]
[R03AC19, olodaterol, The risk or severity of hypokalemia can be increased when Difluocortolone is combined with Olodaterol.]
[L03AB13, peginterferon beta-1a, The risk or severity of adverse effects can be increased when Difluocortolone is combined with Peginterferon beta-1a.]
[V08AA01, diatrizoic acid, Diatrizoate may decrease the excretion rate of Difluocortolone which could result in a higher serum level.]
[V08AA04, iothalamic acid, Diatrizoate may decrease the excretion rate of Difluocortolone which could result in a higher serum level.]
[N05CM19, suvorexant, The metabolism of Suvorexant can be increased when combined with Difluocortolone.]
[S01AA15, dihydrostreptomycin, Dihydrostreptomycin may decrease the excretion rate of Difluocortolone which could result in a higher serum level.]
[V04CX03, methacholine, Difluocortolone may decrease effectiveness of Methacholine as a diagnostic agent.]
[A10BJ05, dulaglutide, The risk or severity of hyperglycemia can be increased when Difluocortolone is combined with Dulaglutide.]
[L01BC08, decitabine, The risk or severity of adverse effects can be increased when Decitabine is combined with Difluocortolone.]
[L04AX05, pirfenidone, The risk or severity of adverse effects can be increased when Pirfenidone is combined with Difluocortolone.]
[L01EX09, nintedanib, The metabolism of Nintedanib can be increased when combined with Difluocortolone.]
[S03AA06, gentamicin, Difluocortolone may decrease the excretion rate of Gentamicin which could result in a higher serum level.]
[L01FX07, blinatumomab, The risk or severity of adverse effects can be increased when Blinatumomab is combined with Difluocortolone.]
[L01XK01, olaparib, The metabolism of Olaparib can be increased when combined with Difluocortolone.]
[B01AA01, dicumarol, Difluocortolone may increase the anticoagulant activities of Dicoumarol.]
[B01AF03, edoxaban, Edoxaban may decrease the excretion rate of Difluocortolone which could result in a higher serum level.]
[L04AC10, secukinumab, The risk or severity of adverse effects can be increased when Secukinumab is combined with Difluocortolone.]
[L01EF01, palbociclib, The metabolism of Palbociclib can be increased when combined with Difluocortolone.]
[L01XH03, panobinostat, The metabolism of Panobinostat can be increased when combined with Difluocortolone.]
[J05AP07, daclatasvir, The metabolism of Daclatasvir can be increased when combined with Difluocortolone.]
[N02BE01, acetaminophen, Acetaminophen may decrease the excretion rate of Difluocortolone which could result in a higher serum level.]
[L01DC01, bleomycin, The risk or severity of adverse effects can be increased when Bleomycin is combined with Difluocortolone.]
[B01AA11, tioclomarol, Difluocortolone may increase the anticoagulant activities of Tioclomarol.]
[J05AF08, adefovir dipivoxil, Adefovir dipivoxil may decrease the excretion rate of Difluocortolone which could result in a higher serum level.]
[J05AP06, asunaprevir, The metabolism of Asunaprevir can be increased when combined with Difluocortolone.]
[L01XJ02, sonidegib, The metabolism of Sonidegib can be increased when combined with Difluocortolone.]
[A06AD03, magnesium peroxide, The bioavailability of Difluocortolone can be decreased when combined with Magnesium peroxide.]
[A10BF01, acarbose, The risk or severity of hyperglycemia can be increased when Difluocortolone is combined with Acarbose.]
[M02AA25, aceclofenac, The risk or severity of gastrointestinal irritation can be increased when Difluocortolone is combined with Aceclofenac.]
[M01AB11, acemetacin, The risk or severity of gastrointestinal irritation can be increased when Difluocortolone is combined with Acemetacin.]
[S01EC01, acetazolamide, Acetazolamide may increase the excretion rate of Difluocortolone which could result in a lower serum level and potentially a reduction in efficacy.]
[A10AE06, insulin degludec, The risk or severity of hyperglycemia can be increased when Difluocortolone is combined with Insulin degludec.]
[V03AB37, idarucizumab, Difluocortolone may decrease the excretion rate of Idarucizumab which could result in a higher serum level.]
[L01CX01, trabectedin, The metabolism of Trabectedin can be increased when combined with Difluocortolone.]
[R03DX09, mepolizumab, The risk or severity of adverse effects can be increased when Mepolizumab is combined with Difluocortolone.]
[J02AC05, isavuconazole, The metabolism of Difluocortolone can be decreased when combined with Isavuconazole.]
[L01EB04, osimertinib, The metabolism of Osimertinib can be increased when combined with Difluocortolone.]
[J05AF13, tenofovir alafenamide, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Difluocortolone.]
[L01EE02, cobimetinib, The metabolism of Cobimetinib can be increased when combined with Difluocortolone.]
[L01XG03, ixazomib, The metabolism of Ixazomib can be increased when combined with Difluocortolone.]
[L01ED03, alectinib, The metabolism of Alectinib can be increased when combined with Difluocortolone.]
[A10BB31, acetohexamide, The risk or severity of hyperglycemia can be increased when Difluocortolone is combined with Acetohexamide.]
[M04AB05, lesinurad, Difluocortolone may decrease the excretion rate of Lesinurad which could result in a higher serum level.]
[J05AP10, elbasvir, The metabolism of Elbasvir can be increased when combined with Difluocortolone.]
[M01AE16, alminoprofen, The risk or severity of gastrointestinal irritation can be increased when Difluocortolone is combined with Alminoprofen.]
[A02AB06, aloglutamol, The bioavailability of Difluocortolone can be decreased when combined with Aloglutamol.]
[N03AX23, brivaracetam, Brivaracetam may decrease the excretion rate of Difluocortolone which could result in a higher serum level.]
[L04AC13, ixekizumab, The risk or severity of adverse effects can be increased when Difluocortolone is combined with Ixekizumab.]
[L01XX52, venetoclax, The metabolism of Venetoclax can be increased when combined with Difluocortolone.]
[N05BA08, bromazepam, Bromazepam may decrease the excretion rate of Difluocortolone which could result in a higher serum level.]
[N04BC01, bromocriptine, The risk or severity of hyperglycemia can be increased when Difluocortolone is combined with Bromocriptine.]
[A02AD05, aluminum magnesium silicate, The bioavailability of Difluocortolone can be decreased when combined with Almasilate.]
[A02AB03, aluminum phosphate, The bioavailability of Difluocortolone can be decreased when combined with Aluminium phosphate.]
[C08CA01, amlodipine, The metabolism of Amlodipine can be increased when combined with Difluocortolone.]
[N05AX17, pimavanserin, The metabolism of Pimavanserin can be increased when combined with Difluocortolone.]
[C03CA02, bumetanide, The risk or severity of hypokalemia can be increased when Difluocortolone is combined with Bumetanide.]
[N01BB01, bupivacaine, Levobupivacaine may decrease the excretion rate of Difluocortolone which could result in a higher serum level.]
[N07BC01, buprenorphine, The metabolism of Buprenorphine can be increased when combined with Difluocortolone.]
[N05BE01, buspirone, The metabolism of Buspirone can be increased when combined with Difluocortolone.]
[L01AB01, busulfan, The metabolism of Busulfan can be increased when combined with Difluocortolone.]
[L01XX27, arsenic trioxide, The risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Difluocortolone.]
[N06DA03, rivastigmine, The therapeutic efficacy of Rivastigmine can be decreased when used in combination with Difluocortolone.]
[P01BE02, artemether, The metabolism of Artemether can be increased when combined with Difluocortolone.]
[M02AA03, clofezone, Rabeprazole may decrease the excretion rate of Difluocortolone which could result in a higher serum level.]
[J01MA09, sparfloxacin, The risk or severity of tendinopathy can be increased when Difluocortolone is combined with Sparfloxacin.]
[S01GX07, azelastine, The metabolism of Azelastine can be increased when combined with Difluocortolone.]
[S01AA26, azithromycin, The metabolism of Azithromycin can be increased when combined with Difluocortolone.]
[L04AC12, brodalumab, The risk or severity of adverse effects can be increased when Difluocortolone is combined with Brodalumab.]
[L01EF02, ribociclib, The metabolism of Difluocortolone can be decreased when combined with Ribociclib.]
[A07EC04, balsalazide, The risk or severity of gastrointestinal irritation can be increased when Difluocortolone is combined with Balsalazide.]
[R03CC12, bambuterol, The therapeutic efficacy of Bambuterol can be decreased when used in combination with Difluocortolone.]
[L04AA36, ocrelizumab, The risk or severity of adverse effects can be increased when Difluocortolone is combined with Ocrelizumab.]
[A06AH05, naldemedine, Difluocortolone may decrease the excretion rate of Naldemedine which could result in a higher serum level.]
[N07XX16, deutetrabenazine, The metabolism of Deutetrabenazine can be increased when combined with Difluocortolone.]
[N02BF02, pregabalin, Pregabalin may decrease the excretion rate of Difluocortolone which could result in a higher serum level.]
[A10BX06, benfluorex, The risk or severity of hyperglycemia can be increased when Difluocortolone is combined with Benfluorex.]
[H05BX05, calcifediol, The therapeutic efficacy of Calcifediol can be decreased when used in combination with Difluocortolone.]
[D05AX03, calcitriol, The therapeutic efficacy of Calcitriol can be decreased when used in combination with Difluocortolone.]
[A12AA04, calcium carbonate, The bioavailability of Difluocortolone can be decreased when combined with Calcium carbonate.]
[P01CA02, benznidazole, Difluocortolone may decrease the excretion rate of Benznidazole which could result in a higher serum level.]
[L04AC01, daclizumab, The risk or severity of adverse effects can be increased when Daclizumab is combined with Difluocortolone.]
[J01XX08, linezolid, The risk or severity of adverse effects can be increased when Linezolid is combined with Difluocortolone.]
[J05AF06, abacavir, Abacavir may decrease the excretion rate of Difluocortolone which could result in a higher serum level.]
[J05AE09, tipranavir, The metabolism of Difluocortolone can be decreased when combined with Tipranavir.]
[N07XX13, valbenazine, The metabolism of Valbenazine can be increased when combined with Difluocortolone.]
[L04AB02, infliximab, The risk or severity of adverse effects can be increased when Infliximab is combined with Difluocortolone.]
[L01EX10, midostaurin, The metabolism of Difluocortolone can be decreased when combined with Midostaurin.]
[L01ED04, brigatinib, The metabolism of Brigatinib can be increased when combined with Difluocortolone.]
[L04AC14, sarilumab, The risk or severity of adverse effects can be increased when Difluocortolone is combined with Sarilumab.]
[J01MA23, delafloxacin, The risk or severity of tendinopathy can be increased when Difluocortolone is combined with Delafloxacin.]
[L04AC16, guselkumab, The risk or severity of adverse effects can be increased when Difluocortolone is combined with Guselkumab.]
[L01BC06, capecitabine, The risk or severity of adverse effects can be increased when Capecitabine is combined with Difluocortolone.]
[L01XX59, enasidenib, The metabolism of Enasidenib can be increased when combined with Difluocortolone.]
[L01EH02, neratinib, The metabolism of Neratinib can be increased when combined with Difluocortolone.]
[L01XH01, vorinostat, The risk or severity of adverse effects can be increased when Vorinostat is combined with Difluocortolone.]
[L01EM02, copanlisib, The metabolism of Copanlisib can be increased when combined with Difluocortolone.]
[L01EF03, abemaciclib, The metabolism of Abemaciclib can be increased when combined with Difluocortolone.]
[C07AB07, bisoprolol, Bisoprolol may decrease the excretion rate of Difluocortolone which could result in a higher serum level.]
[R03AC17, bitolterol, The risk or severity of hypokalemia can be increased when Difluocortolone is combined with Bitolterol.]
[J05AG03, efavirenz, The metabolism of Difluocortolone can be decreased when combined with Efavirenz.]
[J01DC10, cefprozil, Cefprozil may decrease the excretion rate of Difluocortolone which could result in a higher serum level.]
[L04AC02, basiliximab, The risk or severity of adverse effects can be increased when Basiliximab is combined with Difluocortolone.]
[L01BA03, raltitrexed, The risk or severity of adverse effects can be increased when Raltitrexed is combined with Difluocortolone.]
[C03DA03, canrenone, Canrenone may increase the excretion rate of Difluocortolone which could result in a lower serum level and potentially a reduction in efficacy.]
[R03BA02, budesonide, The risk or severity of adverse effects can be increased when Budesonide is combined with Difluocortolone.]
[M01AB07, bumadizone, The risk or severity of gastrointestinal irritation can be increased when Difluocortolone is combined with Bumadizone.]
[L01EL02, acalabrutinib, The metabolism of Acalabrutinib can be increased when combined with Difluocortolone.]
[C01AA02, acetyldigoxins, The risk or severity of adverse effects can be increased when Difluocortolone is combined with Acetyldigoxin.]
[A10BJ06, semaglutide, The risk or severity of hyperglycemia can be increased when Difluocortolone is combined with Semaglutide.]
[N01BX04, capsaicin, The therapeutic efficacy of Capsaicin can be decreased when used in combination with Difluocortolone.]
[A10BK04, ertugliflozin, The risk or severity of hyperglycemia can be increased when Difluocortolone is combined with Ertugliflozin.]
[R06AX18, acrivastine, Difluocortolone may decrease the excretion rate of Acrivastine which could result in a higher serum level.]
[V04CD06, macimorelin, The therapeutic efficacy of Macimorelin can be decreased when used in combination with Difluocortolone.]
[L02BB05, apalutamide, The metabolism of Difluocortolone can be increased when combined with Apalutamide.]
[N03AF01, carbamazepine, The metabolism of Carbamazepine can be increased when combined with Difluocortolone.]
[L03AB06, interferon alfa-n1, The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Difluocortolone.]
[L04AA37, baricitinib, The risk or severity of adverse effects can be increased when Difluocortolone is combined with Baricitinib.]
[J01DE01, cefepime, Cefepime may decrease the excretion rate of Difluocortolone which could result in a higher serum level.]
[J01DD10, cefetamet, Cefetamet may decrease the excretion rate of Difluocortolone which could result in a higher serum level.]
[J01DD09, cefodizime, Cefodizime may decrease the excretion rate of Difluocortolone which could result in a higher serum level.]
[J01DC11, ceforanide, Ceforanide may decrease the excretion rate of Difluocortolone which could result in a higher serum level.]
[J01DD13, cefpodoxime, Cefpodoxime may decrease the excretion rate of Difluocortolone which could result in a higher serum level.]
[J01DD14, ceftibuten, Ceftibuten may decrease the excretion rate of Difluocortolone which could result in a higher serum level.]
[J01GB14, plazomicin, Difluocortolone may decrease the excretion rate of Plazomicin which could result in a higher serum level.]
[C07AB08, celiprolol, The risk or severity of hypokalemia can be increased when Difluocortolone is combined with Celiprolol.]
[L01XX62, ivosidenib, The metabolism of Difluocortolone can be increased when combined with Ivosidenib.]
[A16AX14, migalastat, Migalastat may decrease the excretion rate of Difluocortolone which could result in a higher serum level.]
[N03AX17, stiripentol, The metabolism of Difluocortolone can be decreased when combined with Stiripentol.]
[J05AG06, doravirine, The metabolism of Doravirine can be increased when combined with Difluocortolone.]
[L01EM04, duvelisib, The metabolism of Duvelisib can be increased when combined with Difluocortolone.]
[L01EB07, dacomitinib, The metabolism of Dacomitinib can be increased when combined with Difluocortolone.]
[S01GX12, cetirizine, Cetirizine may decrease the excretion rate of Difluocortolone which could result in a higher serum level.]
[A10BB06, carbutamide, The risk or severity of hyperglycemia can be increased when Difluocortolone is combined with Carbutamide.]
[D08AE05, chloroxylenol, Difluocortolone may decrease the excretion rate of Chloroxylenol which could result in a higher serum level.]
[M01AC05, lornoxicam, The risk or severity of gastrointestinal irritation can be increased when Difluocortolone is combined with Lornoxicam.]
[N07XX15, inotersen, Inotersen may decrease the excretion rate of Difluocortolone which could result in a higher serum level.]
[L01ED05, lorlatinib, The metabolism of Lorlatinib can be increased when combined with Difluocortolone.]
[L04AA39, emapalumab, The risk or severity of adverse effects can be increased when Difluocortolone is combined with Emapalumab.]
[L01AD01, carmustine, The risk or severity of adverse effects can be increased when Carmustine is combined with Difluocortolone.]
[L01EX13, gilteritinib, The metabolism of Gilteritinib can be increased when combined with Difluocortolone.]
[L04AA43, ravulizumab, The risk or severity of adverse effects can be increased when Difluocortolone is combined with Ravulizumab.]
[A06AX05, prucalopride, Prucalopride may decrease the excretion rate of Difluocortolone which could result in a higher serum level.]
[B01AC23, cilostazol, The metabolism of Cilostazol can be increased when combined with Difluocortolone.]
[L04AA42, siponimod, The metabolism of Siponimod can be increased when combined with Difluocortolone.]
[J01FA09, clarithromycin, The metabolism of Difluocortolone can be decreased when combined with Clarithromycin.]
[N06BA14, solriamfetol, Difluocortolone may decrease the excretion rate of Solriamfetol which could result in a higher serum level.]
[L01EN01, erdafitinib, The metabolism of Erdafitinib can be increased when combined with Difluocortolone.]
[N05BA09, clobazam, Clobazam may decrease the excretion rate of Difluocortolone which could result in a higher serum level.]
[H02AB14, cloprednol, The risk or severity of adverse effects can be increased when Difluocortolone is combined with Cloprednol.]
[L04AB01, etanercept, The risk or severity of adverse effects can be increased when Etanercept is combined with Difluocortolone.]
[H02AB17, cortivazol, The risk or severity of adverse effects can be increased when Difluocortolone is combined with Cortivazol.]
[L04AC18, risankizumab, The risk or severity of adverse effects can be increased when Difluocortolone is combined with Risankizumab.]
[L01EM03, alpelisib, The metabolism of Alpelisib can be increased when combined with Difluocortolone.]
[J01DC04, cefaclor, Cefaclor may decrease the excretion rate of Difluocortolone which could result in a higher serum level.]
[J01DB05, cefadroxil, Cefadroxil may decrease the excretion rate of Difluocortolone which could result in a higher serum level.]
[J01DC03, cefamandole, Cefamandole may decrease the excretion rate of Difluocortolone which could result in a higher serum level.]
[J01DB07, cefatrizine, Cefatrizine may decrease the excretion rate of Difluocortolone which could result in a higher serum level.]
[J01DB04, cefazolin, Cefazolin may decrease the excretion rate of Difluocortolone which could result in a higher serum level.]
[J01DC09, cefmetazole, Cefmetazole may decrease the excretion rate of Difluocortolone which could result in a higher serum level.]
[J01DC06, cefonicid, Cefonicid may decrease the excretion rate of Difluocortolone which could result in a higher serum level.]
[L01EX15, pexidartinib, The metabolism of Pexidartinib can be increased when combined with Difluocortolone.]
[J01DD12, cefoperazone, Cefoperazone may decrease the excretion rate of Difluocortolone which could result in a higher serum level.]
[J01DD01, cefotaxime, Cefotaxime may decrease the excretion rate of Difluocortolone which could result in a higher serum level.]
[J01DC05, cefotetan, Cefotetan may decrease the excretion rate of Difluocortolone which could result in a higher serum level.]
[J01DC07, cefotiam, Cefotiam may decrease the excretion rate of Difluocortolone which could result in a higher serum level.]
[J01DC01, cefoxitin, Cefoxitin may decrease the excretion rate of Difluocortolone which could result in a higher serum level.]
[J01DD03, cefsulodin, Cefsulodin may decrease the excretion rate of Difluocortolone which could result in a higher serum level.]
[J01DD02, ceftazidime, Ceftazidime may decrease the excretion rate of Difluocortolone which could result in a higher serum level.]
[C03BX03, cicletanine, Cicletanine may increase the excretion rate of Difluocortolone which could result in a lower serum level and potentially a reduction in efficacy.]
[J01DD07, ceftizoxime, Ceftizoxime may decrease the excretion rate of Difluocortolone which could result in a higher serum level.]
[J01DD04, ceftriaxone, Ceftriaxone may decrease the excretion rate of Difluocortolone which could result in a higher serum level.]
[S01AA27, cefuroxime, Cefuroxime may decrease the excretion rate of Difluocortolone which could result in a higher serum level.]
[L04AA44, upadacitinib, The risk or severity of adverse effects can be increased when Difluocortolone is combined with Upadacitinib.]
[L01EX14, entrectinib, The metabolism of Entrectinib can be increased when combined with Difluocortolone.]
[N07XX11, pitolisant, The serum concentration of Difluocortolone can be decreased when it is combined with Pitolisant.]
[J04AK08, pretomanid, The metabolism of Pretomanid can be increased when combined with Difluocortolone.]
[J01XX12, lefamulin, The metabolism of Lefamulin can be increased when combined with Difluocortolone.]
[N04CX01, istradefylline, The metabolism of Istradefylline can be increased when combined with Difluocortolone.]
[C03AA09, cyclothiazide, The risk or severity of electrolyte imbalance can be increased when Difluocortolone is combined with Cyclothiazide.]
[A10AE03, insulin, regular, pork, The risk or severity of hyperglycemia can be increased when Difluocortolone is combined with Insulin pork.]
[J01XX09, daptomycin, Daptomycin may decrease the excretion rate of Difluocortolone which could result in a higher serum level.]
[J01DB01, cephalexin, The metabolism of Cephalexin can be increased when combined with Difluocortolone.]
[J01DB02, cephaloridine, Cefaloridine may decrease the excretion rate of Difluocortolone which could result in a higher serum level.]
[J01DB03, cephalothin, Cefalotin may decrease the excretion rate of Difluocortolone which could result in a higher serum level.]
[J01DB08, cephapirin, Cefapirin may decrease the excretion rate of Difluocortolone which could result in a higher serum level.]
[J01DB09, cephradine, Cefradine may decrease the excretion rate of Difluocortolone which could result in a higher serum level.]
[H02AB13, deflazacort, The risk or severity of adverse effects can be increased when Difluocortolone is combined with Deflazacort.]
[G03DB05, demegestone, The serum concentration of Difluocortolone can be increased when it is combined with Demegestone.]
[L01FD01, trastuzumab, Trastuzumab may increase the neutropenic activities of Difluocortolone.]
[L01FD03, ado-trastuzumab emtansine, The metabolism of Trastuzumab emtansine can be increased when combined with Difluocortolone.]
[L04AX09, diroximel fumarate, The risk or severity of adverse effects can be increased when Difluocortolone is combined with Diroximel fumarate.]
[L01EL03, zanubrutinib, The metabolism of Zanubrutinib can be increased when combined with Difluocortolone.]
[G03AC09, desogestrel, The serum concentration of Difluocortolone can be increased when it is combined with Desogestrel.]
[N03AX25, cenobamate, The serum concentration of Difluocortolone can be decreased when it is combined with Cenobamate.]
[A16AX16, givosiran, Givosiran may decrease the excretion rate of Difluocortolone which could result in a higher serum level.]
[M09AX08, golodirsen, Difluocortolone may decrease the excretion rate of Golodirsen which could result in a higher serum level.]
[S01XA12, dexpanthenol, The therapeutic efficacy of Dexpanthenol can be decreased when used in combination with Difluocortolone.]
[N05CM21, lemborexant, The metabolism of Lemborexant can be increased when combined with Difluocortolone.]
[L01XX72, tazemetostat, The metabolism of Tazemetostat can be increased when combined with Difluocortolone.]
[L04AA53, teprotumumab, The risk or severity of adverse effects can be increased when Teprotumumab is combined with Difluocortolone.]
[S01AE06, gatifloxacin, The risk or severity of tendinopathy can be increased when Difluocortolone is combined with Gatifloxacin.]
[J05AE05, amprenavir, The metabolism of Difluocortolone can be decreased when combined with Amprenavir.]
[G04CB02, dutasteride, The metabolism of Dutasteride can be increased when combined with Difluocortolone.]
[L04AA38, ozanimod, The risk or severity of adverse effects can be increased when Difluocortolone is combined with Ozanimod.]
[L01EE04, selumetinib, The metabolism of Selumetinib can be increased when combined with Difluocortolone.]
[R02AA03, dichlorobenzyl alcohol, Difluocortolone may decrease the excretion rate of Dichlorobenzyl alcohol which could result in a higher serum level.]
[G03DB08, dienogest, The serum concentration of Difluocortolone can be increased when it is combined with Dienogest.]
[M01AH02, rofecoxib, The risk or severity of gastrointestinal irritation can be increased when Difluocortolone is combined with Rofecoxib.]
[L01XF03, bexarotene, The risk or severity of adverse effects can be increased when Bexarotene is combined with Difluocortolone.]
[C08CA16, clevidipine, Clevidipine may decrease the excretion rate of Difluocortolone which could result in a higher serum level.]
[C01BD07, dronedarone, The metabolism of Dronedarone can be increased when combined with Difluocortolone.]
[L01AA02, chlorambucil, The risk or severity of adverse effects can be increased when Chlorambucil is combined with Difluocortolone.]
[S03AA08, chloramphenicol, The risk or severity of adverse effects can be increased when Chloramphenicol is combined with Difluocortolone.]
[L01EH03, tucatinib, The metabolism of Tucatinib can be decreased when combined with Difluocortolone.]
[D07XB03, fluprednidene, The risk or severity of adverse effects can be increased when Fluprednidene is combined with Difluocortolone.]
[M01AC04, droxicam, The risk or severity of gastrointestinal irritation can be increased when Difluocortolone is combined with Droxicam.]
[V08CA05, mangafodipir, Mangafodipir may decrease the excretion rate of Difluocortolone which could result in a higher serum level.]
[M02AA27, dexketoprofen, The risk or severity of gastrointestinal irritation can be increased when Difluocortolone is combined with Dexketoprofen.]
[L04AA47, inebilizumab, The risk or severity of infection can be increased when Difluocortolone is combined with Inebilizumab.]
[R05CB11, stepronin, The risk or severity of adverse effects can be increased when Stepronin is combined with Difluocortolone.]
[C08CA17, levamlodipine, The metabolism of Levamlodipine can be increased when combined with Difluocortolone.]
[R06AX22, ebastine, The metabolism of Ebastine can be increased when combined with Difluocortolone.]
[L04AC19, satralizumab, The serum concentration of Difluocortolone can be decreased when it is combined with Satralizumab.]
[P01BA01, chloroquine, The metabolism of Chloroquine can be increased when combined with Difluocortolone.]
[C03AA04, chlorothiazide, The risk or severity of electrolyte imbalance can be increased when Difluocortolone is combined with Chlorothiazide.]
[R06AB04, chlorpheniramine, The metabolism of Chlorpheniramine can be increased when combined with Difluocortolone.]
[N05AA01, chlorpromazine, The therapeutic efficacy of Chlorpromazine can be decreased when used in combination with Difluocortolone.]
[A10BB02, chlorpropamide, The risk or severity of hyperglycemia can be increased when Difluocortolone is combined with Chlorpropamide.]
[C03BA04, chlorthalidone, Difluocortolone may increase the hypokalemic activities of Chlorthalidone.]
[M03BB03, chlorzoxazone, Chlorzoxazone may decrease the excretion rate of Difluocortolone which could result in a higher serum level.]
[A11CC05, cholecalciferol, The therapeutic efficacy of Cholecalciferol can be decreased when used in combination with Difluocortolone.]
[N02BA07, ethenzamide, The risk or severity of gastrointestinal irritation can be increased when Difluocortolone is combined with Ethenzamide.]
[C10AC01, cholestyramine resin, Cholestyramine may increase the excretion rate of Difluocortolone which could result in a lower serum level and potentially a reduction in efficacy.]
[N02BA03, choline salicylate, Difluocortolone may decrease the excretion rate of Choline salicylate which could result in a higher serum level.]
[G03DC06, ethynodiol, The serum concentration of Difluocortolone can be increased when it is combined with Etynodiol.]
[M01AB08, etodolac, The risk or severity of gastrointestinal irritation can be increased when Difluocortolone is combined with Etodolac.]
[M02AA06, etofenamate, The risk or severity of gastrointestinal irritation can be increased when Difluocortolone is combined with Etofenamate.]
[B06AC06, berotralstat, The metabolism of Difluocortolone can be decreased when combined with Berotralstat.]
[A16AX20, lonafarnib, The metabolism of Difluocortolone can be decreased when combined with Lonafarnib.]
[L01BB05, fludarabine, The risk or severity of adverse effects can be increased when Fludarabine is combined with Difluocortolone.]
[L02BX04, relugolix, The metabolism of Relugolix can be increased when combined with Difluocortolone.]
[M01AX25, chondroitin sulfates, Difluocortolone may decrease the excretion rate of Chondroitin sulfate which could result in a higher serum level.]
[L04AD03, voclosporin, The risk or severity of adverse effects can be increased when Difluocortolone is combined with Voclosporin.]
[P03AX07, abametapir, The serum concentration of Difluocortolone can be increased when it is combined with Abametapir.]
[M01AE05, fenbufen, The risk or severity of gastrointestinal irritation can be increased when Difluocortolone is combined with Fenbufen.]
[C01CA19, fenoldopam, Fenoldopam may decrease the excretion rate of Difluocortolone which could result in a higher serum level.]
[G04CB01, finasteride, The metabolism of Finasteride can be increased when combined with Difluocortolone.]
[J01DD15, cefdinir, Cefdinir may decrease the excretion rate of Difluocortolone which could result in a higher serum level.]
[J01MB07, flumequine, The risk or severity of tendinopathy can be increased when Difluocortolone is combined with Flumequine.]
[R03BA03, flunisolide, The risk or severity of adverse effects can be increased when Flunisolide is combined with Difluocortolone.]
[N02BG07, flupirtine, Flupirtine may decrease the excretion rate of Difluocortolone which could result in a higher serum level.]
[R03CC15, formoterol, The risk or severity of hypokalemia can be increased when Difluocortolone is combined with Formoterol.]
[A10AF01, insulin, regular, human, The risk or severity of hyperglycemia can be increased when Difluocortolone is combined with Insulin human.]
[L04AA50, ponesimod, The risk or severity of adverse effects can be increased when Difluocortolone is combined with Ponesimod.]
[L03AB10, peginterferon alfa-2b, The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Difluocortolone.]
[A02BA01, cimetidine, Cimetidine may decrease the excretion rate of Difluocortolone which could result in a higher serum level.]
[V08CA04, gadoteridol, Gadoteridol may decrease the excretion rate of Difluocortolone which could result in a higher serum level.]
[J01MB06, cinoxacin, The risk or severity of tendinopathy can be increased when Difluocortolone is combined with Cinoxacin.]
[L01XX73, sotorasib, The serum concentration of Difluocortolone can be decreased when it is combined with Sotorasib.]
[L01EN03, infigratinib, The metabolism of Infigratinib can be increased when combined with Difluocortolone.]
[S03AA07, ciprofloxacin, The risk or severity of tendinopathy can be increased when Difluocortolone is combined with Ciprofloxacin.]
[L01XA01, cisplatin, The therapeutic efficacy of Cisplatin can be decreased when used in combination with Difluocortolone.]
[L04AA54, pegcetacoplan, The risk or severity of adverse effects can be increased when Difluocortolone is combined with Pegcetacoplan.]
[H01AC07, somapacitan, The serum concentration of the active metabolites of Difluocortolone can be decreased when Difluocortolone is used in combination with Somapacitan.]
[C03DA05, finerenone, Finerenone may increase the excretion rate of Difluocortolone which could result in a lower serum level and potentially a reduction in efficacy.]
[L04AA48, belumosudil, The risk or severity of adverse effects can be increased when Difluocortolone is combined with Belumosudil.]
[P01CA03, fexinidazole, The metabolism of Fexinidazole can be increased when combined with Difluocortolone.]
[L04AA51, anifrolumab, The risk or severity of adverse effects can be increased when Difluocortolone is combined with Anifrolumab.]
[H01AC09, lonapegsomatropin, The serum concentration of the active metabolites of Difluocortolone can be decreased when Difluocortolone is used in combination with Lonapegsomatropin.]
[L01EB10, mobocertinib, The metabolism of Mobocertinib can be increased when combined with Difluocortolone.]
[V09AB03, ioflupane I-123, Ioflupane I-123 may decrease the excretion rate of Difluocortolone which could result in a higher serum level.]
[V09AA01, technetium Tc 99m exametazime, Difluocortolone may decrease the excretion rate of Technetium Tc-99m exametazime which could result in a higher serum level.]
[V09AX06, florbetaben f-18, Difluocortolone may decrease the excretion rate of Florbetaben (18F) which could result in a higher serum level.]
[A10BB12, glimepiride, The risk or severity of hyperglycemia can be increased when Difluocortolone is combined with Glimepiride.]
[A10BB08, gliquidone, The risk or severity of hyperglycemia can be increased when Difluocortolone is combined with Gliquidone.]
[R03CC13, clenbuterol, The risk or severity of hypokalemia can be increased when Difluocortolone is combined with Clenbuterol.]
[J01FF01, clindamycin, The metabolism of Clindamycin can be increased when combined with Difluocortolone.]
[N06AX25, St. John's wort extract, The metabolism of Difluocortolone can be increased when combined with St. John's Wort.]
[L03AB15, ropeginterferon alfa-2b, The risk or severity of adverse effects can be increased when Difluocortolone is combined with Ropeginterferon alfa-2b.]
[N01BB10, levobupivacaine, Levobupivacaine may decrease the excretion rate of Difluocortolone which could result in a higher serum level.]
[N06AA04, clomipramine, The metabolism of Clomipramine can be increased when combined with Difluocortolone.]
[N03AE01, clonazepam, Clonazepam may decrease the excretion rate of Difluocortolone which could result in a higher serum level.]
[S01EA04, clonidine, The metabolism of Clonidine can be increased when combined with Difluocortolone.]
[C01EB24, mavacamten, The serum concentration of Difluocortolone can be decreased when it is combined with Mavacamten.]
[J05AH02, oseltamivir, Oseltamivir may decrease the excretion rate of Difluocortolone which could result in a higher serum level.]
[A10BX16, tirzepatide, The risk or severity of hyperglycemia can be increased when Difluocortolone is combined with Tirzepatide.]
[C03BA03, clopamide, Clopamide may increase the excretion rate of Difluocortolone which could result in a lower serum level and potentially a reduction in efficacy.]
[A02BC08, vonoprazan, The metabolism of Vonoprazan can be increased when combined with Difluocortolone.]
[L04AC22, spesolimab, The risk or severity of adverse effects can be increased when Difluocortolone is combined with Spesolimab.]
[L04AA56, deucravacitinib, The risk or severity of adverse effects can be increased when Difluocortolone is combined with Deucravacitinib.]
[A04AA01, ondansetron, The metabolism of Ondansetron can be increased when combined with Difluocortolone.]
[N05AH02, clozapine, The metabolism of Difluocortolone can be decreased when combined with Clozapine.]
[A10BX01, guar gum, The risk or severity of hyperglycemia can be increased when Difluocortolone is combined with Guar gum.]
[A10BK06, sotagliflozin, The risk or severity of hyperglycemia can be increased when Difluocortolone is combined with Sotagliflozin.]
[J01GB12, arbekacin, Difluocortolone may decrease the excretion rate of Arbekacin which could result in a higher serum level.]
[H01AC08, somatrogon, The serum concentration of the active metabolites of Difluocortolone can be reduced when Difluocortolone is used in combination with Somatrogon resulting in a loss in efficacy.]
[L04AC21, bimekizumab, The risk or severity of adverse effects can be increased when Difluocortolone is combined with Bimekizumab.]
[M01AX13, proquazone, The risk or severity of gastrointestinal irritation can be increased when Difluocortolone is combined with Proquazone.]
[M03AC05, hexafluorenium, The therapeutic efficacy of Hexafluronium can be decreased when used in combination with Difluocortolone.]
[M04AC01, colchicine, Colchicine may decrease the excretion rate of Difluocortolone which could result in a higher serum level.]
[J01XB01, colistin, Difluocortolone may decrease the excretion rate of Colistin which could result in a higher serum level.]
[J01DE02, cefpirome, Cefpirome may decrease the excretion rate of Difluocortolone which could result in a higher serum level.]
[L04AA13, leflunomide, The risk or severity of adverse effects can be increased when Difluocortolone is combined with Leflunomide.]
[A02AD04, hydrotalcite, The bioavailability of Difluocortolone can be decreased when combined with Hydrotalcite.]
[A04AA03, tropisetron, Difluocortolone may decrease the excretion rate of Tropisetron which could result in a higher serum level.]
[A10BX03, nateglinide, The risk or severity of hyperglycemia can be increased when Difluocortolone is combined with Nateglinide.]
[N02BA16, imidazole-2-hydroxybenzoate, The risk or severity of gastrointestinal irritation can be increased when Difluocortolone is combined with Imidazole salicylate.]
[H01AC03, mecasermin, The risk or severity of hyperglycemia can be increased when Difluocortolone is combined with Mecasermin.]
[L01BB07, nelarabine, The risk or severity of adverse effects can be increased when Nelarabine is combined with Difluocortolone.]
[A10AE04, insulin glargine, The risk or severity of hyperglycemia can be increased when Difluocortolone is combined with Insulin glargine.]
[J01FA15, telithromycin, The metabolism of Difluocortolone can be decreased when combined with Telithromycin.]
[R03BA08, ciclesonide, The risk or severity of adverse effects can be increased when Ciclesonide is combined with Difluocortolone.]
[B01AC10, indobufen, The risk or severity of gastrointestinal irritation can be increased when Difluocortolone is combined with Indobufen.]
[J05AB14, valganciclovir, Valganciclovir may decrease the excretion rate of Difluocortolone which could result in a higher serum level.]
[C05BB03, invert sugar, Difluocortolone may decrease the excretion rate of Invert sugar which could result in a higher serum level.]
[V08AB09, iodixanol, Iodixanol may decrease the excretion rate of Difluocortolone which could result in a higher serum level.]
[V08AB05, iopromide, Difluocortolone may decrease the excretion rate of Iopromide which could result in a higher serum level.]
[V08AB07, ioversol, Difluocortolone may decrease the excretion rate of Ioversol which could result in a higher serum level.]
[V08AB12, ioxilan, Difluocortolone may decrease the excretion rate of Ioxilan which could result in a higher serum level.]
[M01AH03, valdecoxib, The risk or severity of gastrointestinal irritation can be increased when Difluocortolone is combined with Valdecoxib.]
[H01AX01, pegvisomant, The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Difluocortolone.]
[C01AA06, lanatoside C, The risk or severity of adverse effects can be increased when Difluocortolone is combined with Lanatoside C.]
[N02CC05, almotriptan, Almotriptan may decrease the excretion rate of Difluocortolone which could result in a higher serum level.]
[M01AH04, parecoxib, The risk or severity of gastrointestinal irritation can be increased when Difluocortolone is combined with Parecoxib.]
[J02AC02, itraconazole, The metabolism of Difluocortolone can be decreased when combined with Itraconazole.]
[S01AD03, acyclovir, Acyclovir may decrease the excretion rate of Difluocortolone which could result in a higher serum level.]
[N05BA10, ketazolam, Ketazolam may decrease the excretion rate of Difluocortolone which could result in a higher serum level.]
[M01AA06, kebuzone, The risk or severity of gastrointestinal irritation can be increased when Difluocortolone is combined with Kebuzone.]
[L01EA01, imatinib, The risk or severity of adverse effects can be increased when Imatinib is combined with Difluocortolone.]
[J02AC04, posaconazole, The metabolism of Difluocortolone can be decreased when combined with Posaconazole.]
[N03AX09, lamotrigine, Lamotrigine may decrease the excretion rate of Difluocortolone which could result in a higher serum level.]
[N07BC04, lofexidine, Lofexidine may decrease the excretion rate of Difluocortolone which could result in a higher serum level.]
[S01AE04, lomefloxacin, The risk or severity of tendinopathy can be increased when Difluocortolone is combined with Lomefloxacin.]
[M01AB09, lonazolac, The risk or severity of gastrointestinal irritation can be increased when Difluocortolone is combined with Lonazolac.]
[M02AA31, loxoprofen, The risk or severity of gastrointestinal irritation can be increased when Difluocortolone is combined with Loxoprofen.]
[J01DC08, loracarbef, Loracarbef may decrease the excretion rate of Difluocortolone which could result in a higher serum level.]
[C09AA03, lisinopril, Lisinopril may decrease the excretion rate of Difluocortolone which could result in a higher serum level.]
[A02AD02, magaldrate, The bioavailability of Difluocortolone can be decreased when combined with Magaldrate.]
[A06AD01, magnesium carbonate, The bioavailability of Difluocortolone can be decreased when combined with Magnesium carbonate.]
[H02AB15, meprednisone, The risk or severity of adverse effects can be increased when Difluocortolone is combined with Meprednisone.]
[J01DH02, meropenem, Meropenem may decrease the excretion rate of Difluocortolone which could result in a higher serum level.]
[C03DA04, eplerenone, Eplerenone may increase the excretion rate of Difluocortolone which could result in a lower serum level and potentially a reduction in efficacy.]
[N05AD03, metylperon, Difluocortolone may decrease the excretion rate of Melperone which could result in a higher serum level.]
[L04AA15, alefacept, The risk or severity of adverse effects can be increased when Alefacept is combined with Difluocortolone.]
[C03AA07, cyclopenthiazide, The risk or severity of electrolyte imbalance can be increased when Difluocortolone is combined with Cyclopenthiazide.]
[A10BF02, miglitol, The risk or severity of hyperglycemia can be increased when Difluocortolone is combined with Miglitol.]
[J05AF07, tenofovir disoproxil, Tenofovir disoproxil may decrease the excretion rate of Difluocortolone which could result in a higher serum level.]
[L01AA01, cyclophosphamide, The metabolism of Cyclophosphamide can be increased when combined with Difluocortolone.]
[N06AX07, minaprine, The therapeutic efficacy of Minaprine can be decreased when used in combination with Difluocortolone.]
[S01XA18, cyclosporine, Difluocortolone may increase the immunosuppressive activities of Cyclosporine.]
[N06BA07, modafinil, The metabolism of Modafinil can be increased when combined with Difluocortolone.]
[C10AA07, rosuvastatin, The metabolism of Rosuvastatin can be increased when combined with Difluocortolone.]
[M02AA02, mofebutazone, The risk or severity of gastrointestinal irritation can be increased when Difluocortolone is combined with Mofebutazone.]
[M01AX22, morniflumate, The risk or severity of gastrointestinal irritation can be increased when Difluocortolone is combined with Morniflumate.]
[C03XA02, conivaptan, The metabolism of Difluocortolone can be decreased when combined with Conivaptan.]
[L01BC01, cytarabine, The risk or severity of adverse effects can be increased when Cytarabine is combined with Difluocortolone.]
[G04BE09, vardenafil, The metabolism of Vardenafil can be increased when combined with Difluocortolone.]
[M01AH05, etoricoxib, The risk or severity of gastrointestinal irritation can be increased when Difluocortolone is combined with Etoricoxib.]
[L01AX04, dacarbazine, The risk or severity of adverse effects can be increased when Dacarbazine is combined with Difluocortolone.]
[L01DA01, dactinomycin, The risk or severity of adverse effects can be increased when Dactinomycin is combined with Difluocortolone.]
[G03XA01, danazol, The metabolism of Difluocortolone can be decreased when combined with Danazol.]
[J04BA02, dapsone, The metabolism of Dapsone can be increased when combined with Difluocortolone.]
[L01DB02, daunorubicin, The risk or severity of adverse effects can be increased when Daunorubicin is combined with Difluocortolone.]
[M01AX01, nabumetone, The risk or severity of gastrointestinal irritation can be increased when Difluocortolone is combined with Nabumetone.]
[N07BB05, nalmefene, Nalmefene may decrease the excretion rate of Difluocortolone which could result in a higher serum level.]
[S01GX04, nedocromil, Nedocromil may decrease the excretion rate of Difluocortolone which could result in a higher serum level.]
[N06AX06, nefazodone, The metabolism of Difluocortolone can be decreased when combined with Nefazodone.]
[C01DX16, nicorandil, The risk or severity of ulceration can be increased when Difluocortolone is combined with Nicorandil.]
[L02BB02, nilutamide, Nilutamide may decrease the excretion rate of Difluocortolone which could result in a higher serum level.]
[G03DB04, nomegestrol, The serum concentration of Difluocortolone can be increased when it is combined with Nomegestrol.]
[M03AC11, cisatracurium, The risk or severity of myopathy and weakness can be increased when Cisatracurium is combined with Difluocortolone.]
[B01AX05, fondaparinux, Fondaparinux may decrease the excretion rate of Difluocortolone which could result in a higher serum level.]
[D11AH02, pimecrolimus, The risk or severity of adverse effects can be increased when Pimecrolimus is combined with Difluocortolone.]
[A07EC03, olsalazine, The risk or severity of gastrointestinal irritation can be increased when Difluocortolone is combined with Olsalazine.]
[N06AA01, desipramine, Desipramine may decrease the excretion rate of Difluocortolone which could result in a higher serum level.]
[C01AA07, deslanoside, The risk or severity of adverse effects can be increased when Difluocortolone is combined with Deslanoside.]
[H01BA02, desmopressin, Desmopressin may decrease the excretion rate of Difluocortolone which could result in a higher serum level.]
[D07XC02, desoximetasone, The risk or severity of adverse effects can be increased when Desoximetasone is combined with Difluocortolone.]
[V04CH02, indigo carmine, Difluocortolone may decrease the excretion rate of Indigotindisulfonic acid which could result in a higher serum level.]
[J01DH03, ertapenem, Ertapenem may decrease the excretion rate of Difluocortolone which could result in a higher serum level.]
[L01XA03, oxaliplatin, The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Difluocortolone.]
[M01AE12, oxaprozin, The risk or severity of gastrointestinal irritation can be increased when Difluocortolone is combined with Oxaprozin.]
[S03BA01, dexamethasone, The risk or severity of adverse effects can be increased when Dexamethasone is combined with Difluocortolone.]
[G04BD04, oxybutynin, The metabolism of Oxybutynin can be increased when combined with Difluocortolone.]
[L04AB04, adalimumab, The risk or severity of adverse effects can be increased when Adalimumab is combined with Difluocortolone.]
[L01EB01, gefitinib, The metabolism of Gefitinib can be increased when combined with Difluocortolone.]
[N06BA02, dextroamphetamine, Amphetamine may decrease the excretion rate of Difluocortolone which could result in a higher serum level.]
[R05DA09, dextromethorphan, The metabolism of Dextromethorphan can be increased when combined with Difluocortolone.]
[B01AC04, clopidogrel, The metabolism of Clopidogrel can be increased when combined with Difluocortolone.]
[P03AC04, permethrin, Permethrin may decrease the excretion rate of Difluocortolone which could result in a higher serum level.]
[N05BA01, diazepam, The metabolism of Diazepam can be increased when combined with Difluocortolone.]
[S02DA04, dibucaine, The therapeutic efficacy of Cinchocaine can be decreased when used in combination with Difluocortolone.]
[R05DA08, pholcodine, Difluocortolone may decrease the excretion rate of Pholcodine which could result in a higher serum level.]
[S01EC02, dichlorphenamide, Diclofenamide may increase the excretion rate of Difluocortolone which could result in a lower serum level and potentially a reduction in efficacy.]
[S01BC03, diclofenac, The risk or severity of gastrointestinal irritation can be increased when Difluocortolone is combined with Diclofenac.]
[J05AD01, foscarnet, Foscarnet may decrease the excretion rate of Difluocortolone which could result in a higher serum level.]
[A03AA07, dicyclomine, Dicyclomine may decrease the excretion rate of Difluocortolone which could result in a higher serum level.]
[J05AF02, didanosine, Didanosine may decrease the excretion rate of Difluocortolone which could result in a higher serum level.]
[A10BG03, pioglitazone, The risk or severity of hyperglycemia can be increased when Difluocortolone is combined with Pioglitazone.]
[L01DC04, ixabepilone, The metabolism of Ixabepilone can be increased when combined with Difluocortolone.]
[L01EB02, erlotinib, The metabolism of Erlotinib can be increased when combined with Difluocortolone.]
[L01DB08, pirarubicin, The risk or severity of adverse effects can be increased when Difluocortolone is combined with Pirarubicin.]
[R03CC07, pirbuterol, The risk or severity of hypokalemia can be increased when Difluocortolone is combined with Pirbuterol.]
[C03CA03, piretanide, The risk or severity of hypokalemia can be increased when Difluocortolone is combined with Piretanide.]
[P02CB02, diethylcarbamazine, The therapeutic efficacy of Diethylcarbamazine can be decreased when used in combination with Difluocortolone.]
[L02AA01, diethylstilbestrol, The serum concentration of Difluocortolone can be increased when it is combined with Diethylstilbestrol.]
[C08CA03, isradipine, The metabolism of Difluocortolone can be decreased when combined with Isradipine.]
[L04AA03, lymphocyte immune globulin, anti-thymocyte globulin, equine, The risk or severity of adverse effects can be increased when Difluocortolone is combined with Antilymphocyte immunoglobulin (horse).]
[S01AA13, fusidic acid, The metabolism of Difluocortolone can be decreased when combined with Fusidic acid.]
[J01MB04, pipemidic acid, The risk or severity of tendinopathy can be increased when Difluocortolone is combined with Pipemidic acid.]
[S02BA08, fluocinolone acetonide, The risk or severity of adverse effects can be increased when Fluocinolone acetonide is combined with Difluocortolone.]
[M01AG01, mefenamic acid, The risk or severity of gastrointestinal irritation can be increased when Difluocortolone is combined with Mefenamic acid.]
[C01DA05, pentaerythritol tetranitrate, Pentaerythritol tetranitrate may decrease the excretion rate of Difluocortolone which could result in a higher serum level.]
[N02BA11, diflunisal, The risk or severity of gastrointestinal irritation can be increased when Difluocortolone is combined with Diflunisal.]
[C01AA04, digitoxin, The risk or severity of adverse effects can be increased when Difluocortolone is combined with Digitoxin.]
[C01AA05, digoxin, The risk or severity of adverse effects can be increased when Difluocortolone is combined with Digoxin.]
[L01XX24, pegaspargase, The risk or severity of adverse effects can be increased when Pegaspargase is combined with Difluocortolone.]
[C04AE04, dihydroergocristine, The metabolism of Dihydroergocristine can be increased when combined with Difluocortolone.]
[N02CA01, dihydroergotamine, The metabolism of Dihydroergotamine can be increased when combined with Difluocortolone.]
[N02AA03, hydromorphone, Hydromorphone may decrease the excretion rate of Difluocortolone which could result in a higher serum level.]
[L04AX04, lenalidomide, The risk or severity of adverse effects can be increased when Lenalidomide is combined with Difluocortolone.]
[A11CC02, dihydrotachysterol, The therapeutic efficacy of Dihydrotachysterol can be decreased when used in combination with Difluocortolone.]
[J05AE08, atazanavir, The metabolism of Difluocortolone can be decreased when combined with Atazanavir.]
[H03BC01, potassium perchlorate, Difluocortolone may decrease the excretion rate of Potassium perchlorate which could result in a higher serum level.]
[V03AB04, pralidoxime, Pralidoxime may decrease the excretion rate of Difluocortolone which could result in a higher serum level.]
[C08DB01, diltiazem, The metabolism of Difluocortolone can be decreased when combined with Diltiazem.]
[V03AB09, dimercaprol, Dimercaprol may decrease the excretion rate of Difluocortolone which could result in a higher serum level.]
[R03CC08, procaterol, The risk or severity of hypokalemia can be increased when Difluocortolone is combined with Procaterol.]
[M02AX03, dimethyl sulfoxide, Dimethyl sulfoxide may decrease the excretion rate of Difluocortolone which could result in a higher serum level.]
[N02BB04, propyphenazone, The risk or severity of gastrointestinal irritation can be increased when Difluocortolone is combined with Propyphenazone.]
[M01AB14, proglumetacin, The risk or severity of gastrointestinal irritation can be increased when Difluocortolone is combined with Proglumetacin.]
[A03FA02, cisapride, The metabolism of Cisapride can be increased when combined with Difluocortolone.]
[S01XA23, sirolimus, The metabolism of Sirolimus can be increased when combined with Difluocortolone.]
[S01AX06, resorcinol, Difluocortolone may decrease the excretion rate of Resorcinol which could result in a higher serum level.]
[C01BA03, disopyramide, The risk or severity of hyperglycemia can be increased when Difluocortolone is combined with Disopyramide.]
[L04AA23, natalizumab, The risk or severity of adverse effects can be increased when Difluocortolone is combined with Natalizumab.]
[N07AA03, distigmine, The therapeutic efficacy of Distigmine can be decreased when used in combination with Difluocortolone.]
[P03AA04, disulfiram, The metabolism of Disulfiram can be increased when combined with Difluocortolone.]
[S02AA12, rifamycin SV, The metabolism of Difluocortolone can be increased when combined with Rifamycin.]
[J04AB05, rifapentine, The metabolism of Difluocortolone can be increased when combined with Rifapentine.]
[N05AX08, risperidone, The metabolism of Risperidone can be increased when combined with Difluocortolone.]
[R06AE09, levocetirizine, Levocetirizine may decrease the excretion rate of Difluocortolone which could result in a higher serum level.]
[L04AA21, efalizumab, The risk or severity of adverse effects can be increased when Efalizumab is combined with Difluocortolone.]
[N01BB09, ropivacaine, Ropivacaine may decrease the excretion rate of Difluocortolone which could result in a higher serum level.]
[J01MB01, rosoxacin, The risk or severity of tendinopathy can be increased when Difluocortolone is combined with Rosoxacin.]
[L01EX01, sunitinib, The risk or severity of hyperglycemia can be increased when Difluocortolone is combined with Sunitinib.]
[A04AD12, aprepitant, The metabolism of Difluocortolone can be decreased when combined with Aprepitant.]
[C03XA01, tolvaptan, The metabolism of Tolvaptan can be increased when combined with Difluocortolone.]
[L01XG01, bortezomib, The metabolism of Bortezomib can be increased when combined with Difluocortolone.]
[G04BE08, tadalafil, The metabolism of Tadalafil can be increased when combined with Difluocortolone.]
[S01BC05, ketorolac, The risk or severity of gastrointestinal irritation can be increased when Difluocortolone is combined with Ketorolac.]
[C02KX02, ambrisentan, The metabolism of Ambrisentan can be increased when combined with Difluocortolone.]
[C01EB18, ranolazine, Ranolazine may decrease the excretion rate of Difluocortolone which could result in a higher serum level.]
[N02BA06, salsalate, The risk or severity of gastrointestinal irritation can be increased when Difluocortolone is combined with Salsalate.]
[R03AC12, salmeterol, The risk or severity of hypokalemia can be increased when Difluocortolone is combined with Salmeterol.]
[H05BA01, salmon calcitonin, Salmon calcitonin may decrease the excretion rate of Difluocortolone which could result in a higher serum level.]
[C01CA07, dobutamine, The risk or severity of hypokalemia can be increased when Difluocortolone is combined with Dobutamine.]
[A03FA03, domperidone, The metabolism of Domperidone can be increased when combined with Difluocortolone.]
[C01CA04, dopamine, Dopamine may decrease the excretion rate of Difluocortolone which could result in a higher serum level.]
[N06AA12, doxepin, Doxepin may decrease the excretion rate of Difluocortolone which could result in a higher serum level.]
[L01DB01, doxorubicin, The metabolism of Doxorubicin can be increased when combined with Difluocortolone.]
[J01AA02, doxycycline, Doxycycline may decrease the excretion rate of Difluocortolone which could result in a higher serum level.]
[A08AA10, sibutramine, Sibutramine may decrease the excretion rate of Difluocortolone which could result in a higher serum level.]
[C10AA01, simvastatin, The metabolism of Simvastatin can be increased when combined with Difluocortolone.]
[B05XA02, sodium bicarbonate, The bioavailability of Difluocortolone can be decreased when combined with Sodium bicarbonate.]
[A12CA02, sodium sulfate, Difluocortolone may decrease the excretion rate of Sodium sulfate which could result in a higher serum level.]
[R03DA01, dyphylline, Dyphylline may decrease the excretion rate of Difluocortolone which could result in a higher serum level.]
[N02CC01, sumatriptan, Sumatriptan may decrease the excretion rate of Difluocortolone which could result in a higher serum level.]
[V04CX07, edrophonium, The therapeutic efficacy of Edrophonium can be decreased when used in combination with Difluocortolone.]
[H01AA01, corticotropin, The risk or severity of adverse effects can be increased when Corticotropin is combined with Difluocortolone.]
[J01MA05, temafloxacin, The risk or severity of tendinopathy can be increased when Difluocortolone is combined with Temafloxacin.]
[L01AX03, temozolomide, The risk or severity of adverse effects can be increased when Temozolomide is combined with Difluocortolone.]
[M01AC02, tenoxicam, The risk or severity of gastrointestinal irritation can be increased when Difluocortolone is combined with Tenoxicam.]
[N06AX14, tianeptine, The metabolism of Tianeptine can be increased when combined with Difluocortolone.]
[M01AG02, tolfenamic acid, The risk or severity of gastrointestinal irritation can be increased when Difluocortolone is combined with Tolfenamic acid.]
[N06AG03, toloxatone, Difluocortolone may decrease the excretion rate of Toloxatone which could result in a higher serum level.]
[N06BA09, atomoxetine, Atomoxetine may decrease the excretion rate of Difluocortolone which could result in a higher serum level.]
[N03AX11, topiramate, Topiramate may decrease the excretion rate of Difluocortolone which could result in a higher serum level.]
[C03CA04, torsemide, The risk or severity of hypokalemia can be increased when Difluocortolone is combined with Torasemide.]
[H02CA01, trilostane, The risk or severity of edema formation can be increased when Trilostane is combined with Difluocortolone.]
[L01AA07, trofosfamide, The risk or severity of adverse effects can be increased when Difluocortolone is combined with Trofosfamide.]
[J01MA04, enoxacin, The risk or severity of tendinopathy can be increased when Difluocortolone is combined with Enoxacin.]
[L01CA04, vinorelbine, The metabolism of Vinorelbine can be increased when combined with Difluocortolone.]
[S01FB02, ephedrine, Ephedrine may increase the excretion rate of Difluocortolone which could result in a lower serum level and potentially a reduction in efficacy.]
[N06AX16, venlafaxine, Venlafaxine may decrease the excretion rate of Difluocortolone which could result in a higher serum level.]
[C08CA12, mepirodipine, The metabolism of Difluocortolone can be decreased when combined with Barnidipine.]
[S01EA01, epinephrine, The risk or severity of hypokalemia can be increased when Difluocortolone is combined with Epinephrine.]
[L01DB03, epirubicin, The risk or severity of adverse effects can be increased when Epirubicin is combined with Difluocortolone.]
[N05CF02, zolpidem, The metabolism of Zolpidem can be increased when combined with Difluocortolone.]
[M01AB04, zomepirac, The risk or severity of gastrointestinal irritation can be increased when Difluocortolone is combined with Zomepirac.]
[N03AX15, zonisamide, Zonisamide may increase the excretion rate of Difluocortolone which could result in a lower serum level and potentially a reduction in efficacy.]
[A10AB06, insulin glulisine, human, The risk or severity of hyperglycemia can be increased when Difluocortolone is combined with Insulin glulisine.]
[L01XA02, carboplatin, The risk or severity of adverse effects can be increased when Carboplatin is combined with Difluocortolone.]
[C02AC02, guanfacine, Guanfacine may decrease the excretion rate of Difluocortolone which could result in a higher serum level.]
[A11CC01, ergocalciferol, The therapeutic efficacy of Ergocalciferol can be decreased when used in combination with Difluocortolone.]
[N02CA02, ergotamine, The metabolism of Difluocortolone can be decreased when combined with Ergotamine.]
[L03AX05, pidotimod, Difluocortolone may decrease the excretion rate of Pidotimod which could result in a higher serum level.]
[S01AA17, erythromycin, The metabolism of Difluocortolone can be decreased when combined with Erythromycin.]
[N05CD04, estazolam, Estazolam may decrease the excretion rate of Difluocortolone which could result in a higher serum level.]
[A02BC02, pantoprazole, Pantoprazole may decrease the excretion rate of Difluocortolone which could result in a higher serum level.]
[G03CA03, estradiol, The serum concentration of Difluocortolone can be increased when it is combined with Estradiol.]
[L01XX11, estramustine, The risk or severity of adverse effects can be increased when Estramustine is combined with Difluocortolone.]
[G03CA57, estrogens, conjugated (USP), Conjugated estrogens may decrease the excretion rate of Difluocortolone which could result in a higher serum level.]
[J04AK02, ethambutol, Ethambutol may decrease the excretion rate of Difluocortolone which could result in a higher serum level.]
[R03BA09, fluticasone furoate, The risk or severity of adverse effects can be increased when Fluticasone furoate is combined with Difluocortolone.]
[R03BA05, fluticasone, The risk or severity of adverse effects can be increased when Difluocortolone is combined with Fluticasone.]
[C10AA04, fluvastatin, The metabolism of Fluvastatin can be increased when combined with Difluocortolone.]
[V08CA03, gadodiamide, Gadodiamide may decrease the excretion rate of Difluocortolone which could result in a higher serum level.]
[L02AA03, ethinyl estradiol, The serum concentration of Difluocortolone can be increased when it is combined with Ethinylestradiol.]
[C01BD05, ibutilide, Ibutilide may decrease the excretion rate of Difluocortolone which could result in a higher serum level.]
[N04AA05, profenamine, The therapeutic efficacy of Profenamine can be decreased when used in combination with Difluocortolone.]
[M01AC06, meloxicam, The risk or severity of gastrointestinal irritation can be increased when Difluocortolone is combined with Meloxicam.]
[N01AX07, etomidate, Etomidate may decrease the excretion rate of Difluocortolone which could result in a higher serum level.]
[L01CB01, etoposide, The metabolism of Etoposide can be increased when combined with Difluocortolone.]
[L04AD02, tacrolimus, Tacrolimus may increase the immunosuppressive activities of Difluocortolone.]
[A02BA04, nizatidine, The therapeutic efficacy of Nizatidine can be decreased when used in combination with Difluocortolone.]
[J01MA08, fleroxacin, The risk or severity of tendinopathy can be increased when Difluocortolone is combined with Fleroxacin.]
[R06AX11, astemizole, The metabolism of Astemizole can be increased when combined with Difluocortolone.]
[R06AX12, terfenadine, The metabolism of Difluocortolone can be decreased when combined with Terfenadine.]
[P01AX07, trimetrexate, Trimetrexate may decrease the excretion rate of Difluocortolone which could result in a higher serum level.]
[N06AX12, bupropion, Bupropion may decrease the excretion rate of Difluocortolone which could result in a higher serum level.]
[N06AB08, fluvoxamine, The metabolism of Difluocortolone can be decreased when combined with Fluvoxamine.]
[L02AE02, leuprolide, Leuprolide may decrease the excretion rate of Difluocortolone which could result in a higher serum level.]
[L04AA02, muromonab-CD3, The risk or severity of adverse effects can be increased when Muromonab is combined with Difluocortolone.]
[M01CB01, gold sodium thiomalate, Difluocortolone may decrease the excretion rate of Sodium aurothiomalate which could result in a higher serum level.]
[B05AA05, dextran, Difluocortolone may decrease the excretion rate of Dextran which could result in a higher serum level.]
[V03AF02, dexrazoxane, The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Difluocortolone.]
[A16AA01, levocarnitine, Levocarnitine may decrease the excretion rate of Difluocortolone which could result in a higher serum level.]
[P02CA03, albendazole, The metabolism of Albendazole can be increased when combined with Difluocortolone.]
[C08CA02, felodipine, The metabolism of Felodipine can be increased when combined with Difluocortolone.]
[M01AE04, fenoprofen, The risk or severity of gastrointestinal irritation can be increased when Difluocortolone is combined with Fenoprofen.]
[R03CC04, fenoterol, The risk or severity of hypokalemia can be increased when Difluocortolone is combined with Fenoterol.]
[N02AB03, fentanyl, Fentanyl may decrease the excretion rate of Difluocortolone which could result in a higher serum level.]
[R03CC02, albuterol, The risk or severity of hypokalemia can be increased when Difluocortolone is combined with Salbutamol.]
[L01BB06, clofarabine, The risk or severity of adverse effects can be increased when Clofarabine is combined with Difluocortolone.]
[L04AA40, cladribine, The risk or severity of adverse effects can be increased when Cladribine is combined with Difluocortolone.]
[N07AX03, cevimeline, Cevimeline may decrease the excretion rate of Difluocortolone which could result in a higher serum level.]
[G04BD02, flavoxate, Flavoxate may decrease the excretion rate of Difluocortolone which could result in a higher serum level.]
[N02BG04, floctafenine, The risk or severity of gastrointestinal irritation can be increased when Difluocortolone is combined with Floctafenine.]
[J02AC01, fluconazole, The metabolism of Difluocortolone can be decreased when combined with Fluconazole.]
[J02AX01, flucytosine, The risk or severity of adverse effects can be increased when Flucytosine is combined with Difluocortolone.]
[H02AA02, fludrocortisone, The risk or severity of adverse effects can be increased when Fludrocortisone is combined with Difluocortolone.]
[V03AB25, flumazenil, Flumazenil may decrease the excretion rate of Difluocortolone which could result in a higher serum level.]
[D07AC08, fluocinonide, The risk or severity of adverse effects can be increased when Fluocinonide is combined with Difluocortolone.]
[H02AB03, fluocortolone, The risk or severity of adverse effects can be increased when Fluocortolone is combined with Difluocortolone.]
[L01BC09, floxuridine, The risk or severity of adverse effects can be increased when Floxuridine is combined with Difluocortolone.]
[S01CB05, fluorometholone, The risk or severity of adverse effects can be increased when Fluorometholone is combined with Difluocortolone.]
[L01BC02, fluorouracil, The risk or severity of adverse effects can be increased when Fluorouracil is combined with Difluocortolone.]
[G03BA01, fluoxymesterone, The risk or severity of fluid retention can be increased when Difluocortolone is combined with Fluoxymesterone.]
[N05CD01, flurazepam, Flurazepam may decrease the excretion rate of Difluocortolone which could result in a higher serum level.]
[S01BC04, flurbiprofen, The risk or severity of gastrointestinal irritation can be increased when Difluocortolone is combined with Flurbiprofen.]
[L02BB01, flutamide, The metabolism of Flutamide can be increased when combined with Difluocortolone.]
[V04CX02, folic acid, Folic acid may decrease the excretion rate of Difluocortolone which could result in a higher serum level.]
[S02AA17, fosfomycin, Fosfomycin may decrease the excretion rate of Difluocortolone which could result in a higher serum level.]
[S01AA07, framycetin, Framycetin may decrease the excretion rate of Difluocortolone which could result in a higher serum level.]
[L01BC03, tegafur, The metabolism of Tegafur can be increased when combined with Difluocortolone.]
[M03AA01, alcuronium, The risk or severity of myopathy and weakness can be increased when Alcuronium is combined with Difluocortolone.]
[J05AE10, darunavir, The metabolism of Difluocortolone can be decreased when combined with Darunavir.]
[C03CA01, furosemide, The risk or severity of hypokalemia can be increased when Difluocortolone is combined with Furosemide.]
[N05CF04, eszopiclone, Eszopiclone may decrease the excretion rate of Difluocortolone which could result in a higher serum level.]
[N06DA04, galantamine, The therapeutic efficacy of Galantamine can be decreased when used in combination with Difluocortolone.]
[M03AC02, gallamine, The risk or severity of myopathy and weakness can be increased when Gallamine is combined with Difluocortolone.]
[S01AD09, ganciclovir, Ganciclovir may decrease the excretion rate of Difluocortolone which could result in a higher serum level.]
[C10AB04, gemfibrozil, Gemfibrozil may decrease the excretion rate of Difluocortolone which could result in a higher serum level.]
[J01XA03, telavancin, Telavancin may decrease the excretion rate of Difluocortolone which could result in a higher serum level.]
[L01EA02, dasatinib, The metabolism of Dasatinib can be increased when combined with Difluocortolone.]
[N04BC06, cabergoline, The metabolism of Cabergoline can be increased when combined with Difluocortolone.]
[A10BJ02, liraglutide, The risk or severity of hyperglycemia can be increased when Difluocortolone is combined with Liraglutide.]
[G03XA02, gestrinone, The serum concentration of Difluocortolone can be increased when it is combined with Gestrinone.]
[N01AH02, alfentanil, The metabolism of Alfentanil can be increased when combined with Difluocortolone.]
[L01EH01, lapatinib, The metabolism of Lapatinib can be increased when combined with Difluocortolone.]
[A10BB01, glyburide, The risk or severity of hyperglycemia can be increased when Difluocortolone is combined with Glyburide.]
[A10BB09, gliclazide, The risk or severity of hyperglycemia can be increased when Difluocortolone is combined with Gliclazide.]
[A10BB07, glipizide, The risk or severity of hyperglycemia can be increased when Difluocortolone is combined with Glipizide.]
[N05CM18, dexmedetomidine, Dexmedetomidine may decrease the excretion rate of Difluocortolone which could result in a higher serum level.]
[C01BD04, dofetilide, The metabolism of Dofetilide can be increased when combined with Difluocortolone.]
[C02CA04, doxazosin, The metabolism of Doxazosin can be increased when combined with Difluocortolone.]
[H01AB01, thyrotropin alfa, The therapeutic efficacy of Thyrotropin alfa can be decreased when used in combination with Difluocortolone.]
[L01EX02, sorafenib, The metabolism of Sorafenib can be increased when combined with Difluocortolone.]
[M01CB04, aurothioglucose, Difluocortolone may decrease the excretion rate of Aurothioglucose which could result in a higher serum level.]
[S01LA03, pegaptanib, Pegaptanib may decrease the excretion rate of Difluocortolone which could result in a higher serum level.]
[B01AA12, fluindione, Difluocortolone may increase the anticoagulant activities of Fluindione.]
[C09AA09, fosinopril, Fosinopril may decrease the excretion rate of Difluocortolone which could result in a higher serum level.]
[S01EX01, guanethidine, Guanethidine may decrease the excretion rate of Difluocortolone which could result in a higher serum level.]
[L02AE03, goserelin, Goserelin may decrease the excretion rate of Difluocortolone which could result in a higher serum level.]
[P01BX01, halofantrine, The metabolism of Halofantrine can be increased when combined with Difluocortolone.]
[N05AD01, haloperidol, The serum concentration of Haloperidol can be increased when it is combined with Difluocortolone.]
[N05AH04, quetiapine, The metabolism of Quetiapine can be increased when combined with Difluocortolone.]
[N06BX13, idebenone, Idebenone may decrease the excretion rate of Difluocortolone which could result in a higher serum level.]
[A10AD05, insulin aspart, human, The risk or severity of hyperglycemia can be increased when Difluocortolone is combined with Insulin aspart.]
[L01CE02, irinotecan, The metabolism of Irinotecan can be increased when combined with Difluocortolone.]
[M04AA01, allopurinol, Allopurinol may decrease the excretion rate of Difluocortolone which could result in a higher serum level.]
[G03DC01, allylestrenol, The metabolism of Allylestrenol can be increased when combined with Difluocortolone.]
[A07EC02, mesalamine, The risk or severity of gastrointestinal irritation can be increased when Difluocortolone is combined with Mesalazine.]
[C01CE02, milrinone, Milrinone may decrease the excretion rate of Difluocortolone which could result in a higher serum level.]
[L01XX03, altretamine, The risk or severity of adverse effects can be increased when Altretamine is combined with Difluocortolone.]
[R03CC05, hexoprenaline, The risk or severity of hypokalemia can be increased when Difluocortolone is combined with Hexoprenaline.]
[J05AG01, nevirapine, The metabolism of Nevirapine can be increased when combined with Difluocortolone.]
[C08CA10, nilvadipine, The metabolism of Difluocortolone can be decreased when combined with Nilvadipine.]
[M02AA26, nimesulide, The risk or severity of gastrointestinal irritation can be increased when Difluocortolone is combined with Nimesulide.]
[C09AA04, perindopril, Perindopril may decrease the excretion rate of Difluocortolone which could result in a higher serum level.]
[C02DB02, hydralazine, Hydralazine may decrease the excretion rate of Difluocortolone which could result in a higher serum level.]
[C03AA03, hydrochlorothiazide, The risk or severity of electrolyte imbalance can be increased when Difluocortolone is combined with Hydrochlorothiazide.]
[S02BA01, hydrocortisone, The metabolism of Hydrocortisone can be increased when combined with Difluocortolone.]
[C03AA02, hydroflumethiazide, The risk or severity of electrolyte imbalance can be increased when Difluocortolone is combined with Hydroflumethiazide.]
[B05XA17, potassium acetate, Difluocortolone may decrease the excretion rate of Potassium acetate which could result in a higher serum level.]
[A12BA02, potassium citrate, Potassium citrate may increase the excretion rate of Difluocortolone which could result in a lower serum level and potentially a reduction in efficacy.]
[V03AB33, hydroxocobalamin, Hydroxocobalamin may decrease the excretion rate of Difluocortolone which could result in a higher serum level.]
[G04BD06, propiverine, Difluocortolone may decrease the excretion rate of Propiverine which could result in a higher serum level.]
[P01BA02, hydroxychloroquine, The risk or severity of adverse effects can be increased when Hydroxychloroquine is combined with Difluocortolone.]
[B05AA07, hetastarch, Difluocortolone may decrease the excretion rate of Hydroxyethyl Starch which could result in a higher serum level.]
[L01XX05, hydroxyurea, The risk or severity of adverse effects can be increased when Hydroxyurea is combined with Difluocortolone.]
[N05BB01, hydroxyzine, The metabolism of Hydroxyzine can be increased when combined with Difluocortolone.]
[R02AX02, ibuprofen, The risk or severity of gastrointestinal irritation can be increased when Difluocortolone is combined with Ibuprofen.]
[B05XA08, sodium acetate, Difluocortolone may decrease the excretion rate of Sodium acetate which could result in a higher serum level.]
[L01DB06, idarubicin, The risk or severity of adverse effects can be increased when Idarubicin is combined with Difluocortolone.]
[L01AA06, ifosfamide, The metabolism of Ifosfamide can be increased when combined with Difluocortolone.]
[N06AA02, imipramine, Imipramine may decrease the excretion rate of Difluocortolone which could result in a higher serum level.]
[L01CD01, paclitaxel, The metabolism of Paclitaxel can be increased when combined with Difluocortolone.]
[R01AD07, tixocortol, The risk or severity of adverse effects can be increased when Tixocortol is combined with Difluocortolone.]
[L01CE01, topotecan, The risk or severity of adverse effects can be increased when Topotecan is combined with Difluocortolone.]
[C03BA11, indapamide, Difluocortolone may increase the hypokalemic activities of Indapamide.]
[S01BC01, indomethacin, The risk or severity of gastrointestinal irritation can be increased when Difluocortolone is combined with Indomethacin.]
[A11HA07, inositol, Difluocortolone may decrease the excretion rate of Inositol which could result in a higher serum level.]
[L03AB04, interferon alfa-2a, The risk or severity of adverse effects can be increased when Interferon alfa-2a is combined with Difluocortolone.]
[L03AB05, interferon alfa-2b, The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Difluocortolone.]
[N06AX17, milnacipran, The metabolism of Difluocortolone can be decreased when combined with Milnacipran.]
[S01XA28, varenicline, Varenicline may decrease the excretion rate of Difluocortolone which could result in a higher serum level.]
[L04AA25, eculizumab, The risk or severity of adverse effects can be increased when Eculizumab is combined with Difluocortolone.]
[A10BH01, sitagliptin, The risk or severity of hyperglycemia can be increased when Difluocortolone is combined with Sitagliptin.]
[N05BA12, alprazolam, The metabolism of Alprazolam can be increased when combined with Difluocortolone.]
[N05CH02, ramelteon, Ramelteon may decrease the excretion rate of Difluocortolone which could result in a higher serum level.]
[A10BH02, vildagliptin, The risk or severity of hyperglycemia can be increased when Difluocortolone is combined with Vildagliptin.]
[C10AA06, cerivastatin, The metabolism of Cerivastatin can be increased when combined with Difluocortolone.]
[C03BA02, quinethazone, Difluocortolone may increase the hypokalemic activities of Quinethazone.]
[L03AB09, interferon alfacon-1, The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Difluocortolone.]
[V03AB01, ipecac, Difluocortolone may decrease the excretion rate of Ipecac which could result in a higher serum level.]
[R03CC06, isoetharine, The risk or severity of hypokalemia can be increased when Difluocortolone is combined with Isoetharine.]
[S01EB07, isoflurophate, The therapeutic efficacy of Isoflurophate can be decreased when used in combination with Difluocortolone.]
[J04AC01, isoniazid, The serum concentration of Isoniazid can be decreased when it is combined with Difluocortolone.]
[J05AX05, inosine pranobex, Difluocortolone may decrease the excretion rate of Inosine pranobex which could result in a higher serum level.]
[R03CB01, isoproterenol, The therapeutic efficacy of Isoprenaline can be decreased when used in combination with Difluocortolone.]
[A10BJ01, exenatide, The risk or severity of hyperglycemia can be increased when Difluocortolone is combined with Exenatide.]
[D10BA01, isotretinoin, Isotretinoin may decrease the excretion rate of Difluocortolone which could result in a higher serum level.]
[S01AA24, kanamycin, Difluocortolone may decrease the excretion rate of Kanamycin which could result in a higher serum level.]
[H01AC01, somatropin, The therapeutic efficacy of Somatotropin can be decreased when used in combination with Difluocortolone.]
[A02AB01, aluminum hydroxide, The bioavailability of Difluocortolone can be decreased when combined with Aluminum hydroxide.]
[L04AC07, tocilizumab, The risk or severity of adverse effects can be increased when Tocilizumab is combined with Difluocortolone.]
[N01AX03, ketamine, The therapeutic efficacy of Ketamine can be decreased when used in combination with Difluocortolone.]
[B01AC22, prasugrel, Prasugrel may decrease the excretion rate of Difluocortolone which could result in a higher serum level.]
[J02AB02, ketoconazole, The metabolism of Difluocortolone can be decreased when combined with Ketoconazole.]
[M02AA10, ketoprofen, The risk or severity of gastrointestinal irritation can be increased when Difluocortolone is combined with Ketoprofen.]
[V03AC03, deferasirox, The risk or severity of gastrointestinal ulceration and gastrointestinal irritation can be increased when Difluocortolone is combined with Deferasirox.]
[L04AA24, abatacept, The risk or severity of adverse effects can be increased when Abatacept is combined with Difluocortolone.]
[C01CA22, arbutamine, The risk or severity of hypokalemia can be increased when Difluocortolone is combined with Arbutamine.]
[J01MB02, nalidixic acid, The risk or severity of tendinopathy can be increased when Difluocortolone is combined with Nalidixic acid.]
[M01AE11, tiaprofenic acid, The risk or severity of gastrointestinal irritation can be increased when Difluocortolone is combined with Tiaprofenic acid.]
[C07AG01, labetalol, Labetalol may decrease the excretion rate of Difluocortolone which could result in a higher serum level.]
[N04BB01, amantadine, Amantadine may decrease the excretion rate of Difluocortolone which could result in a higher serum level.]
[N07AA30, ambenonium, The therapeutic efficacy of Ambenonium can be decreased when used in combination with Difluocortolone.]
[A06AX03, lubiprostone, Lubiprostone may decrease the excretion rate of Difluocortolone which could result in a higher serum level.]
[N03AX18, lacosamide, The metabolism of Lacosamide can be increased when combined with Difluocortolone.]
[C03CC01, ethacrynic acid, The risk or severity of hypokalemia can be increased when Difluocortolone is combined with Etacrynic acid.]
[L01DC03, mitomycin, The risk or severity of adverse effects can be increased when Mitomycin is combined with Difluocortolone.]
[G03AD01, levonorgestrel, The serum concentration of Difluocortolone can be increased when it is combined with Levonorgestrel.]
[S02DA01, lidocaine, The metabolism of Lidocaine can be increased when combined with Difluocortolone.]
[S01AA21, amikacin, Difluocortolone may decrease the excretion rate of Amikacin which could result in a higher serum level.]
[C03DB01, amiloride, Amiloride may increase the excretion rate of Difluocortolone which could result in a lower serum level and potentially a reduction in efficacy.]
[L01AD02, lomustine, The risk or severity of adverse effects can be increased when Lomustine is combined with Difluocortolone.]
[N05BA06, lorazepam, Lorazepam may decrease the excretion rate of Difluocortolone which could result in a higher serum level.]
[C10AA02, lovastatin, The metabolism of Difluocortolone can be decreased when combined with Lovastatin.]
[G03DC03, lynestrenol, The serum concentration of Difluocortolone can be increased when it is combined with Lynestrenol.]
[L01EG01, temsirolimus, The metabolism of Temsirolimus can be increased when combined with Difluocortolone.]
[B05XA11, magnesium chloride, Difluocortolone may decrease the excretion rate of Magnesium chloride which could result in a higher serum level.]
[G04BX01, magnesium hydroxide, The bioavailability of Difluocortolone can be decreased when combined with Magnesium hydroxide.]
[A12CC10, magnesium oxide, The bioavailability of Difluocortolone can be decreased when combined with Magnesium oxide.]
[L01BA05, pralatrexate, The risk or severity of adverse effects can be increased when Pralatrexate is combined with Difluocortolone.]
[L01EA03, nilotinib, The metabolism of Difluocortolone can be decreased when combined with Nilotinib.]
[V04CX04, mannitol, Mannitol may increase the excretion rate of Difluocortolone which could result in a lower serum level and potentially a reduction in efficacy.]
[N06AA21, maprotiline, Maprotiline may decrease the excretion rate of Difluocortolone which could result in a higher serum level.]
[C02BB01, mecamylamine, Mecamylamine may decrease the excretion rate of Difluocortolone which could result in a higher serum level.]
[L01AA05, mechlorethamine, The therapeutic efficacy of Mechlorethamine can be decreased when used in combination with Difluocortolone.]
[M02AA18, meclofenamic acid, The risk or severity of gastrointestinal irritation can be increased when Difluocortolone is combined with Meclofenamic acid.]
[C01AA08, medigoxin, The risk or severity of adverse effects can be increased when Difluocortolone is combined with Metildigoxin.]
[P01BC02, mefloquine, The therapeutic efficacy of Mefloquine can be decreased when used in combination with Difluocortolone.]
[C03BA05, mefruside, Mefruside may increase the excretion rate of Difluocortolone which could result in a lower serum level and potentially a reduction in efficacy.]
[L01AA03, melphalan, The risk or severity of adverse effects can be increased when Melphalan is combined with Difluocortolone.]
[N06DX01, memantine, The therapeutic efficacy of Memantine can be decreased when used in combination with Difluocortolone.]
[N02AB02, meperidine, The metabolism of Meperidine can be increased when combined with Difluocortolone.]
[N01BB03, mepivacaine, Mepivacaine may decrease the excretion rate of Difluocortolone which could result in a higher serum level.]
[G04BX16, tiopronin, Tiopronin may decrease the excretion rate of Difluocortolone which could result in a higher serum level.]
[L02BG01, aminoglutethimide, The therapeutic efficacy of Difluocortolone can be decreased when used in combination with Aminoglutethimide.]
[C03BC01, mersalyl, Mersalyl may increase the excretion rate of Difluocortolone which could result in a lower serum level and potentially a reduction in efficacy.]
[G03BB01, mesterolone, The risk or severity of edema formation can be increased when Mesterolone is combined with Difluocortolone.]
[N05AX13, paliperidone, The metabolism of Paliperidone can be increased when combined with Difluocortolone.]
[A10BA02, metformin, The therapeutic efficacy of Metformin can be decreased when used in combination with Difluocortolone.]
[N07BC02, methadone, Methadone may decrease the excretion rate of Difluocortolone which could result in a higher serum level.]
[N06BA03, methamphetamine, Metamfetamine may decrease the excretion rate of Difluocortolone which could result in a higher serum level.]
[J05AF05, lamivudine, Lamivudine may decrease the excretion rate of Difluocortolone which could result in a higher serum level.]
[S01EC05, methazolamide, Methazolamide may increase the excretion rate of Difluocortolone which could result in a lower serum level and potentially a reduction in efficacy.]
[A14AA04, methenolone, The risk or severity of edema formation can be increased when Metenolone is combined with Difluocortolone.]
[H03BB02, methimazole, The metabolism of Difluocortolone can be decreased when combined with Methimazole.]
[L01BA04, pemetrexed, The risk or severity of adverse effects can be increased when Pemetrexed is combined with Difluocortolone.]
[A11HA02, pyridoxine, Pyridoxine may decrease the excretion rate of Difluocortolone which could result in a higher serum level.]
[L04AX03, methotrexate, The metabolism of Methotrexate can be increased when combined with Difluocortolone.]
[D05BA02, methoxsalen, Methoxsalen may decrease the excretion rate of Difluocortolone which could result in a higher serum level.]
[C03AA08, methyclothiazide, The risk or severity of electrolyte imbalance can be increased when Difluocortolone is combined with Methyclothiazide.]
[C02AB01, methyldopa, Methyldopa may decrease the excretion rate of Difluocortolone which could result in a higher serum level.]
[V04CG05, methylene blue, Difluocortolone may decrease the excretion rate of Methylene blue which could result in a higher serum level.]
[R03DA05, aminophylline, The metabolism of Aminophylline can be increased when combined with Difluocortolone.]
[H02AB04, methylprednisolone, The risk or severity of adverse effects can be increased when Methylprednisolone is combined with Difluocortolone.]
[G03EK01, methyltestosterone, The risk or severity of edema formation can be increased when Methyltestosterone is combined with Difluocortolone.]
[N02CA04, methysergide, The metabolism of Methysergide can be increased when combined with Difluocortolone.]
[A03FA01, metoclopramide, The therapeutic efficacy of Metoclopramide can be decreased when used in combination with Difluocortolone.]
[C03BA08, metolazone, Difluocortolone may increase the hypokalemic activities of Metolazone.]
[C07AB02, metoprolol, Metoprolol may decrease the excretion rate of Difluocortolone which could result in a higher serum level.]
[P01AB01, metronidazole, The metabolism of Metronidazole can be increased when combined with Difluocortolone.]
[V04CD01, metyrapone, Metyrapone may decrease the excretion rate of Difluocortolone which could result in a higher serum level.]
[S02AA13, miconazole, The metabolism of Difluocortolone can be decreased when combined with Miconazole.]
[N02BB03, aminopyrine, The risk or severity of gastrointestinal irritation can be increased when Difluocortolone is combined with Aminophenazone.]
[N05CD08, midazolam, The metabolism of Midazolam can be increased when combined with Difluocortolone.]
[G03XB01, mifepristone, The therapeutic efficacy of Difluocortolone can be decreased when used in combination with Mifepristone.]
[J05AH01, zanamivir, Zanamivir may decrease the excretion rate of Difluocortolone which could result in a higher serum level.]
[L01XX23, mitotane, The serum concentration of Difluocortolone can be decreased when it is combined with Mitotane.]
[L01DB07, mitoxantrone, The risk or severity of adverse effects can be increased when Mitoxantrone is combined with Difluocortolone.]
[L03AC01, aldesleukin, The therapeutic efficacy of Aldesleukin can be decreased when used in combination with Difluocortolone.]
[C01BD01, amiodarone, The metabolism of Difluocortolone can be decreased when combined with Amiodarone.]
[N06AA09, amitriptyline, The metabolism of Amitriptyline can be increased when combined with Difluocortolone.]
[A04AA05, palonosetron, Palonosetron may decrease the excretion rate of Difluocortolone which could result in a higher serum level.]
[J01DD06, moxalactam, Latamoxef may decrease the excretion rate of Difluocortolone which could result in a higher serum level.]
[L04AB05, certolizumab pegol, The risk or severity of adverse effects can be increased when Certolizumab pegol is combined with Difluocortolone.]
[G04BA01, ammonium chloride, Ammonium chloride may decrease the excretion rate of Difluocortolone which could result in a higher serum level.]
[L04AA52, ofatumumab, The risk or severity of adverse effects can be increased when Ofatumumab is combined with Difluocortolone.]
[L01EX03, pazopanib, The metabolism of Pazopanib can be increased when combined with Difluocortolone.]
[L04AA06, mycophenolic acid, The risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Difluocortolone.]
[M03AC03, vecuronium, The risk or severity of myopathy and weakness can be increased when Vecuronium is combined with Difluocortolone.]
[N03AB05, fosphenytoin, The serum concentration of Difluocortolone can be decreased when it is combined with Fosphenytoin.]
[L03AB08, interferon beta-1b, The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Difluocortolone.]
[C07AA12, nadolol, Nadolol may decrease the excretion rate of Difluocortolone which could result in a higher serum level.]
[J01CA04, amoxicillin, Amoxicillin may decrease the excretion rate of Difluocortolone which could result in a higher serum level.]
[V03AB15, naloxone, The metabolism of Difluocortolone can be decreased when combined with Naloxone.]
[L04AC03, anakinra, The risk or severity of adverse effects can be increased when Anakinra is combined with Difluocortolone.]
[S01XA11, nandrolone, The risk or severity of edema formation can be increased when Nandrolone phenpropionate is combined with Difluocortolone.]
[N06BA01, amphetamine, Amphetamine may decrease the excretion rate of Difluocortolone which could result in a higher serum level.]
[M02AA12, naproxen, The risk or severity of gastrointestinal irritation can be increased when Difluocortolone is combined with Naproxen.]
[A10BG01, troglitazone, The risk or severity of hyperglycemia can be increased when Difluocortolone is combined with Troglitazone.]
[N06AX21, duloxetine, Duloxetine may decrease the excretion rate of Difluocortolone which could result in a higher serum level.]
[N04BX01, tolcapone, Tolcapone may decrease the excretion rate of Difluocortolone which could result in a higher serum level.]
[L01CD02, docetaxel, The metabolism of Docetaxel can be increased when combined with Difluocortolone.]
[S03AA01, neomycin, Difluocortolone may decrease the excretion rate of Neomycin which could result in a higher serum level.]
[A10BX02, repaglinide, The risk or severity of hyperglycemia can be increased when Difluocortolone is combined with Repaglinide.]
[B01AC17, tirofiban, Tirofiban may decrease the excretion rate of Difluocortolone which could result in a higher serum level.]
[S01EB06, neostigmine, The therapeutic efficacy of Neostigmine can be decreased when used in combination with Difluocortolone.]
[N05AX14, iloperidone, The metabolism of Iloperidone can be increased when combined with Difluocortolone.]
[J02AA01, amphotericin B, The risk or severity of hypokalemia can be increased when Difluocortolone is combined with Amphotericin B.]
[S01AA19, ampicillin, Ampicillin may decrease the excretion rate of Difluocortolone which could result in a higher serum level.]
[L03AX16, plerixafor, Plerixafor may decrease the excretion rate of Difluocortolone which could result in a higher serum level.]
[S01AA23, netilmicin, Difluocortolone may decrease the excretion rate of Netilmicin which could result in a higher serum level.]
[N06AX23, desvenlafaxine, The metabolism of Difluocortolone can be decreased when combined with Desvenlafaxine.]
[J05AB11, valacyclovir, Valaciclovir may decrease the excretion rate of Difluocortolone which could result in a higher serum level.]
[H05BX02, paricalcitol, The therapeutic efficacy of Paricalcitol can be decreased when used in combination with Difluocortolone.]
[C01CE01, inamrinone, Amrinone may decrease the excretion rate of Difluocortolone which could result in a higher serum level.]
[L01XX01, amsacrine, The risk or severity of adverse effects can be increased when Amsacrine is combined with Difluocortolone.]
[C08CA04, nicardipine, The metabolism of Difluocortolone can be decreased when combined with Nicardipine.]
[C08CA05, nifedipine, The metabolism of Nifedipine can be increased when combined with Difluocortolone.]
[M02AA17, niflumic acid, The risk or severity of gastrointestinal irritation can be increased when Difluocortolone is combined with Niflumic acid.]
[C08CA07, nisoldipine, The metabolism of Nisoldipine can be increased when combined with Difluocortolone.]
[C08CA08, nitrendipine, The metabolism of Nitrendipine can be increased when combined with Difluocortolone.]
[R07AX01, nitric oxide, Nitric Oxide may decrease the excretion rate of Difluocortolone which could result in a higher serum level.]
[J01XE01, nitrofurantoin, Nitrofurantoin may decrease the excretion rate of Difluocortolone which could result in a higher serum level.]
[N05CF03, zaleplon, The metabolism of Zaleplon can be increased when combined with Difluocortolone.]
[N04BC05, pramipexole, Pramipexole may decrease the excretion rate of Difluocortolone which could result in a higher serum level.]
[C02DD01, nitroprusside, Nitroprusside may decrease the excretion rate of Difluocortolone which could result in a higher serum level.]
[C01CA03, norepinephrine, The risk or severity of hypokalemia can be increased when Difluocortolone is combined with Norepinephrine.]
[G03DC02, norethindrone, The serum concentration of Difluocortolone can be increased when it is combined with Norethisterone.]
[S01AE02, norfloxacin, The risk or severity of tendinopathy can be increased when Difluocortolone is combined with Norfloxacin.]
[G03AC07, norgestrienone, The serum concentration of Difluocortolone can be increased when it is combined with Norgestrienone.]
[N06AA10, nortriptyline, The metabolism of Nortriptyline can be increased when combined with Difluocortolone.]
[S02AA16, ofloxacin, The risk or severity of tendinopathy can be increased when Difluocortolone is combined with Ofloxacin.]
[L04AC04, rilonacept, The risk or severity of adverse effects can be increased when Rilonacept is combined with Difluocortolone.]
[N02AA02, opium, Difluocortolone may decrease the excretion rate of Opium which could result in a higher serum level.]
[R03CB03, metaproterenol, The risk or severity of hypokalemia can be increased when Difluocortolone is combined with Orciprenaline.]
[G04CA02, tamsulosin, Tamsulosin may decrease the excretion rate of Difluocortolone which could result in a higher serum level.]
[J01CF04, oxacillin, Oxacillin may decrease the excretion rate of Difluocortolone which could result in a higher serum level.]
[A14AA08, oxandrolone, The risk or severity of fluid retention can be increased when Difluocortolone is combined with Oxandrolone.]
[N05BA04, oxazepam, Oxazepam may decrease the excretion rate of Difluocortolone which could result in a higher serum level.]
[J01MB05, oxolinic acid, The risk or severity of tendinopathy can be increased when Difluocortolone is combined with Oxolinic acid.]
[N02AA05, oxycodone, The metabolism of Oxycodone can be increased when combined with Difluocortolone.]
[A14AA05, oxymetholone, The risk or severity of fluid retention can be increased when Difluocortolone is combined with Oxymetholone.]
[S01BC02, oxyphenbutazone, The risk or severity of gastrointestinal irritation can be increased when Difluocortolone is combined with Oxyphenbutazone.]
[M03AC01, pancuronium, The therapeutic efficacy of Pancuronium can be decreased when used in combination with Difluocortolone.]
[J04AB30, capreomycin, Difluocortolone may decrease the excretion rate of Capreomycin which could result in a higher serum level.]
[G03DB06, chlormadinone, The serum concentration of Difluocortolone can be increased when it is combined with Chlormadinone.]
[H02AB05, paramethasone, The risk or severity of adverse effects can be increased when Paramethasone is combined with Difluocortolone.]
[A07AA06, paromomycin, Paromomycin may decrease the excretion rate of Difluocortolone which could result in a higher serum level.]
[J01MA03, pefloxacin, The risk or severity of tendinopathy can be increased when Difluocortolone is combined with Pefloxacin.]
[G04BD11, fesoterodine, Fesoterodine may decrease the excretion rate of Difluocortolone which could result in a higher serum level.]
[C07AA23, penbutolol, Penbutolol may decrease the excretion rate of Difluocortolone which could result in a higher serum level.]
[M01CC01, penicillamine, The risk or severity of adverse effects can be increased when Penicillamine is combined with Difluocortolone.]
[J01CE09, penicillin G procaine, Difluocortolone may decrease the excretion rate of Procaine benzylpenicillin which could result in a higher serum level.]
[J07AF01, diphtheria toxoid vaccine, inactivated, The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Difluocortolone.]
[J07AM01, tetanus toxoid vaccine, inactivated, The therapeutic efficacy of Clostridium tetani toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Difluocortolone.]
[N05CA01, pentobarbital, The metabolism of Difluocortolone can be increased when combined with Pentobarbital.]
[L01XX08, pentostatin, The risk or severity of adverse effects can be increased when Pentostatin is combined with Difluocortolone.]
[C04AD03, pentoxifylline, Pentoxifylline may decrease the excretion rate of Difluocortolone which could result in a higher serum level.]
[J07AJ, pertussis vaccine, The therapeutic efficacy of Pertussis vaccine can be decreased when used in combination with Difluocortolone.]
[G04BX06, phenazopyridine, Phenazopyridine may decrease the excretion rate of Difluocortolone which could result in a higher serum level.]
[N06AF03, phenelzine, Phenelzine may decrease the excretion rate of Difluocortolone which could result in a higher serum level.]
[A10BA01, phenformin, The risk or severity of hyperglycemia can be increased when Difluocortolone is combined with Phenformin.]
[B01AA02, phenindione, Difluocortolone may increase the anticoagulant activities of Phenindione.]
[N03AA02, phenobarbital, The metabolism of Difluocortolone can be increased when combined with Phenobarbital.]
[B01AA04, phenprocoumon, Difluocortolone may increase the anticoagulant activities of Phenprocoumon.]
[V03AB36, phentolamine, Phentolamine may decrease the excretion rate of Difluocortolone which could result in a higher serum level.]
[M02AA01, phenylbutazone, The risk or severity of gastrointestinal irritation can be increased when Difluocortolone is combined with Phenylbutazone.]
[S01GA05, phenylephrine, The risk or severity of hypertension can be increased when Difluocortolone is combined with Phenylephrine.]
[R01BA01, phenylpropanolamine, The risk or severity of hypokalemia can be increased when Difluocortolone is combined with Phenylpropanolamine.]
[N03AB02, phenytoin, The serum concentration of Difluocortolone can be decreased when it is combined with Phenytoin.]
[L04AB06, golimumab, The risk or severity of adverse effects can be increased when Golimumab is combined with Difluocortolone.]
[S01AE05, levofloxacin, The risk or severity of tendinopathy can be increased when Difluocortolone is combined with Levofloxacin.]
[V03AB19, physostigmine, The therapeutic efficacy of Physostigmine can be decreased when used in combination with Difluocortolone.]
[L02BB03, bicalutamide, The metabolism of Bicalutamide can be increased when combined with Difluocortolone.]
[B02BA01, vitamin K1, Phylloquinone may decrease the excretion rate of Difluocortolone which could result in a higher serum level.]
[J05AB12, cidofovir, Cidofovir may decrease the excretion rate of Difluocortolone which could result in a higher serum level.]
[N05AG02, pimozide, The metabolism of Pimozide can be increased when combined with Difluocortolone.]
[C07AA03, pindolol, Pindolol may decrease the excretion rate of Difluocortolone which could result in a higher serum level.]
[C10AA05, atorvastatin, The metabolism of Atorvastatin can be increased when combined with Difluocortolone.]
[J01CA12, piperacillin, Piperacillin may decrease the excretion rate of Difluocortolone which could result in a higher serum level.]
[J05AE01, saquinavir, The metabolism of Difluocortolone can be decreased when combined with Saquinavir.]
[N06BX03, piracetam, Difluocortolone may decrease the excretion rate of Piracetam which could result in a higher serum level.]
[S01BC06, piroxicam, The risk or severity of gastrointestinal irritation can be increased when Difluocortolone is combined with Piroxicam.]
[J01DD16, cefditoren, Cefditoren may decrease the excretion rate of Difluocortolone which could result in a higher serum level.]
[J01MA11, grepafloxacin, The risk or severity of tendinopathy can be increased when Difluocortolone is combined with Grepafloxacin.]
[J05AG02, delavirdine, The metabolism of Difluocortolone can be decreased when combined with Delavirdine.]
[A10BG02, rosiglitazone, The risk or severity of hyperglycemia can be increased when Difluocortolone is combined with Rosiglitazone.]
[L04AC08, canakinumab, The risk or severity of adverse effects can be increased when Canakinumab is combined with Difluocortolone.]
[C03AA05, polythiazide, The risk or severity of electrolyte imbalance can be increased when Difluocortolone is combined with Polythiazide.]
[J05AE03, ritonavir, The serum concentration of Difluocortolone can be increased when it is combined with Ritonavir.]
[A10BH03, saxagliptin, The risk or severity of hyperglycemia can be increased when Difluocortolone is combined with Saxagliptin.]
[B05XA01, potassium chloride, Potassium chloride may decrease the excretion rate of Difluocortolone which could result in a higher serum level.]
[A10AD04, insulin lispro, The risk or severity of hyperglycemia can be increased when Difluocortolone is combined with Insulin lispro.]
[P02BA01, praziquantel, The metabolism of Praziquantel can be increased when combined with Difluocortolone.]
[S03BA02, prednisolone, The risk or severity of adverse effects can be increased when Prednisolone is combined with Difluocortolone.]
[H02AB07, prednisone, The risk or severity of adverse effects can be increased when Prednisone is combined with Difluocortolone.]
[P01BA03, primaquine, The metabolism of Difluocortolone can be decreased when combined with Primaquine.]
[N03AA03, primidone, The metabolism of Difluocortolone can be increased when combined with Primidone.]
[M04AB01, probenecid, Probenecid may decrease the excretion rate of Difluocortolone which could result in a higher serum level.]
[C01BA02, procainamide, The therapeutic efficacy of Procainamide can be decreased when used in combination with Difluocortolone.]
[S01HA05, procaine, The therapeutic efficacy of Procaine can be decreased when used in combination with Difluocortolone.]
[L01XB01, procarbazine, The risk or severity of adverse effects can be increased when Procarbazine is combined with Difluocortolone.]
[C10AB05, fenofibrate, The metabolism of Fenofibrate can be increased when combined with Difluocortolone.]
[G03DA04, progesterone, The serum concentration of Difluocortolone can be increased when it is combined with Progesterone.]
[R06AD02, promethazine, Promethazine may decrease the excretion rate of Difluocortolone which could result in a higher serum level.]
[A03AB05, propantheline, Propantheline may decrease the excretion rate of Difluocortolone which could result in a higher serum level.]
[L01XH02, romidepsin, The metabolism of Romidepsin can be increased when combined with Difluocortolone.]
[C07AA05, propranolol, The metabolism of Propranolol can be increased when combined with Difluocortolone.]
[H03BA02, propylthiouracil, The risk or severity of adverse effects can be increased when Propylthiouracil is combined with Difluocortolone.]
[N02CC04, rizatriptan, Rizatriptan may decrease the excretion rate of Difluocortolone which could result in a higher serum level.]
[B01AC09, epoprostenol, Epoprostenol may decrease the excretion rate of Difluocortolone which could result in a higher serum level.]
[N05AX12, aripiprazole, The metabolism of Aripiprazole can be increased when combined with Difluocortolone.]
[N07XX07, dalfampridine, Dalfampridine may decrease the excretion rate of Difluocortolone which could result in a higher serum level.]
[P02CC01, pyrantel, The risk or severity of myopathy and weakness can be increased when Pyrantel is combined with Difluocortolone.]
[J04AK01, pyrazinamide, Pyrazinamide may decrease the excretion rate of Difluocortolone which could result in a higher serum level.]
[J06BB05, rabies immune globulin, human, The therapeutic efficacy of Rabies immune globulin, human can be decreased when used in combination with Difluocortolone.]
[N07AA02, pyridostigmine, The therapeutic efficacy of Pyridostigmine can be decreased when used in combination with Difluocortolone.]
[P01AX05, quinacrine, The metabolism of Quinacrine can be increased when combined with Difluocortolone.]
[C01BA01, quinidine, The metabolism of Quinidine can be increased when combined with Difluocortolone.]
[P01BC01, quinine, The risk or severity of hyperglycemia can be increased when Difluocortolone is combined with Quinine.]
[A02BA02, ranitidine, Ranitidine may decrease the excretion rate of Difluocortolone which could result in a higher serum level.]
[C02AA02, reserpine, Reserpine may decrease the excretion rate of Difluocortolone which could result in a higher serum level.]
[J05AP01, ribavirin, Ribavirin may decrease the excretion rate of Difluocortolone which could result in a higher serum level.]
[J04AB02, rifampin, The metabolism of Difluocortolone can be increased when combined with Rifampicin.]
[G02CA01, ritodrine, The risk or severity of hypokalemia can be increased when Difluocortolone is combined with Ritodrine.]
[N02BA05, salicylamide, The risk or severity of gastrointestinal irritation can be increased when Difluocortolone is combined with Salicylamide.]
[A07EC01, sulfasalazine, The risk or severity of gastrointestinal irritation can be increased when Difluocortolone is combined with Sulfasalazine.]
[S01BC08, salicylic acid, The risk or severity of gastrointestinal irritation can be increased when Difluocortolone is combined with Salicylic acid.]
[N05CA06, secobarbital, Secobarbital may decrease the excretion rate of Difluocortolone which could result in a higher serum level.]
[L01FA03, obinutuzumab, The risk or severity of adverse effects can be increased when Obinutuzumab is combined with Difluocortolone.]
[J01GB08, sisomicin, Difluocortolone may decrease the excretion rate of Sisomicin which could result in a higher serum level.]
[A12CD01, sodium fluoride, Difluocortolone may decrease the excretion rate of Sodium fluoride which could result in a higher serum level.]
[M05BX04, denosumab, The risk or severity of adverse effects can be increased when Denosumab is combined with Difluocortolone.]
[V04CC01, sorbitol, Sorbitol may decrease the excretion rate of Difluocortolone which could result in a higher serum level.]
[L01CD04, cabazitaxel, The metabolism of Cabazitaxel can be increased when combined with Difluocortolone.]
[L03AX17, sipuleucel-T, The therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Difluocortolone.]
[C03DA01, spironolactone, Spironolactone may increase the excretion rate of Difluocortolone which could result in a lower serum level and potentially a reduction in efficacy.]
[N05CC01, chloral hydrate, Chloral hydrate may decrease the excretion rate of Difluocortolone which could result in a higher serum level.]
[D07AB02, hydrocortisone butyrate, The risk or severity of adverse effects can be increased when Difluocortolone is combined with Hydrocortisone butyrate.]
[C01DA14, isosorbide mononitrate, Isosorbide mononitrate may decrease the excretion rate of Difluocortolone which could result in a higher serum level.]
[H02CA04, levoketoconazole, The metabolism of Difluocortolone can be decreased when combined with Levoketoconazole.]
[D10AX03, azelaic acid, Azelaic acid may decrease the excretion rate of Difluocortolone which could result in a higher serum level.]
